<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy - Eaton, C - 2022 | Cochrane Library</title> <meta content="Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy - Eaton, C - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013136.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy - Eaton, C - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013136.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013136.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy" name="citation_title"/> <meta content="Chris Eaton&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="eatoncb@cardiff.ac.uk" name="citation_author_email"/> <meta content="Kenneith Yong&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Royal Hospital for Children and Young People" name="citation_author_institution"/> <meta content="Victoria Walter" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Gashirai K Mbizvo" name="citation_author"/> <meta content="The Walton Centre NHS Foundation Trust" name="citation_author_institution"/> <meta content="Sinead Rhodes" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Richard FM Chin" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD013136.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013136.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013136.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013136.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [adverse effects]; *Attention Deficit Disorder with Hyperactivity [drug therapy]; *Central Nervous System Stimulants [adverse effects]; *Drug Resistant Epilepsy [drug therapy]; *Drug-Related Side Effects and Adverse Reactions; *Epilepsy [complications, drug therapy]; Iran; Quality of Life; Risperidone [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013136.pub2&amp;doi=10.1002/14651858.CD013136.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013136\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013136\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","ja","hr","fa","pl","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013136.pub2",title:"Stimulant and non\\u2010stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy",firstPublishedDate:"Jul 13, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013136.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013136.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013136.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013136.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013136.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013136.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013136.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013136.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013136.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013136.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7289 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013136.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/appendices#CD013136-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/supinfo/CD013136StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/supinfo/CD013136StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Chris Eaton</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0005">Kenneith Yong</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0006">Victoria Walter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0007">Gashirai K Mbizvo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0008">Sinead Rhodes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information#CD013136-cr-0009">Richard FM Chin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information/en#CD013136-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013136.pub2">https://doi.org/10.1002/14651858.CD013136.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013136-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013136-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013136-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013136-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013136-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013136-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013136-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013136-abs-0001" lang="en"> <section id="CD013136-sec-0001"> <h3 class="title" id="CD013136-sec-0001">Background</h3> <p>Attention Deficit Hyperactivity Disorder (ADHD) can co‐occur in up to 40% of people with epilepsy. There is debate about the efficacy and tolerability of stimulant and non‐stimulant drugs used to treat people with ADHD and co‐occurring epilepsy. </p> </section> <section id="CD013136-sec-0002"> <h3 class="title" id="CD013136-sec-0002">Objectives</h3> <p>To assess the effect of stimulant and non‐stimulant drugs on children and adults with ADHD and co‐occurring epilepsy in terms of seizure frequency and drug withdrawal rates (primary objectives), as well as seizure severity, ADHD symptoms, cognitive state, general behaviour, quality of life, and adverse effects profile (secondary objectives). </p> </section> <section id="CD013136-sec-0003"> <h3 class="title" id="CD013136-sec-0003">Search methods</h3> <p>We searched the following databases on 12 October 2020: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to 9 October 2020), CINAHL Plus (EBSCOhost, 1937 onwards). There were no language restrictions. CRS Web includes randomised or quasi‐randomised controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialised Registers of Cochrane Review Groups including Epilepsy.  </p> </section> <section id="CD013136-sec-0004"> <h3 class="title" id="CD013136-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of stimulant and non‐stimulant drugs for people of any age, gender or ethnicity with ADHD and co‐occurring epilepsy. </p> </section> <section id="CD013136-sec-0005"> <h3 class="title" id="CD013136-sec-0005">Data collection and analysis</h3> <p>We selected articles and extracted data according to predefined criteria. We conducted primary analysis on an intention‐to‐treat basis. We presented outcomes as risk ratios (RRs) with 95% confidence intervals (CIs), except for individual adverse effects where we quoted 99% CIs. We conducted best‐ and worst‐case sensitivity analyses to deal with missing data. We carried out a risk of bias assessment for each included study using the Cochrane risk of bias tool and assessed the overall certainty of evidence using the GRADE approach. </p> </section> <section id="CD013136-sec-0006"> <h3 class="title" id="CD013136-sec-0006">Main results</h3> <p>We identified two studies that matched our inclusion criteria: a USA study compared different doses of the stimulant drug osmotic‐release oral system methylphenidate (OROS‐MPH) with a placebo in 33 children (mean age 10.5 ± 3.0 years), and an Iranian study compared the non‐stimulant drug omega‐3 taken in conjunction with risperidone and usual anti‐seizure medication (ASM) with risperidone and ASM only in 61 children (mean age 9.24 ± 0.15 years). All children were diagnosed with epilepsy and ADHD according to International League Against Epilepsy and Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria, respectively. We assessed both studies to be at low risk of detection and reporting biases, but assessments varied from low to high risk of bias for all other domains. </p> <p><b>OROS‐MPH</b><br/>No participant taking OROS‐MPH experienced significant worsening of epilepsy, defined as: 1. a doubling of the highest 14‐day or highest two‐day seizure rate observed during the 12 months before the trial; 2. a generalised tonic‐clonic seizure if none had been experienced in the previous two years; or 3. a clinically meaningful intensification in seizure duration or severity (33 participants, 1 study; low‐certainty evidence). However, higher doses of OROS‐MPH predicted an increased daily risk of a seizure (P &lt; 0.001; 33 participants, 1 study; low‐certainty evidence). OROS‐MPH had a larger proportion of participants receiving 'much improved' or 'very much improved' scores for ADHD symptoms on the Clinical Global Impressions for ADHD‐Improvement tool (33 participants, 1 study; low‐certainty evidence). OROS‐MPH also had a larger proportion of people withdrawing from treatment (RR 2.80; 95% CI 1.14 to 6.89; 33 participants, 1 study; moderate‐certainty evidence). </p> <p><b>Omega‐3</b><br/>Omega‐3 with risperidone and ASM were associated with a reduction in mean seizure frequency by 6.6 seizures per month (95% CI 4.24 to 8.96; 56 participants, 1 study; low‐certainty evidence) and an increase in the proportion of people achieving 50% or greater reduction in monthly seizure frequency (RR 2.79, 95% CI 0.84 to 9.24; 56 participants, 1 study; low‐certainty evidence) compared to people on risperidone and ASM alone. Omega‐3 with risperidone and ASM also had a smaller proportion of people withdrawing from treatment (RR 0.65, 95% CI 0.12 to 3.59; 61 participants, 1 study; low‐certainty evidence) but a larger proportion of people experiencing adverse drug events (RR 1.40, 95% CI 0.44 to 4.42; 56 participants, 1 study; low‐certainty evidence) compared to people on risperidone and ASM alone. </p> </section> <section id="CD013136-sec-0007"> <h3 class="title" id="CD013136-sec-0007">Authors' conclusions</h3> <p>In children with a dual‐diagnosis of epilepsy and ADHD, there is some evidence that use of the stimulant drug OROS‐MPH is not associated with significant worsening of epilepsy, but higher doses of it may be associated with increased daily risk of seizures; the evidence is of low‐certainty. OROS‐MPH is also associated with improvement in ADHD symptoms. However, this treatment was also associated with a large proportion of treatment withdrawal compared to placebo. In relation to the non‐stimulant drug omega‐3, there is some evidence for reduction in seizure frequency in children who are also on risperidone and ASM, compared to children who are on risperidone and ASM alone. Evidence is inconclusive whether omega‐3 increases or decreases the risk of adverse drug events. </p> <p>We identified only two studies – one each for OROS‐MPH and omega‐3 – with low to high risk of bias. We assessed the overall certainty of evidence for the outcomes of both OROS‐MPH and omega‐3 as low to moderate. </p> <p>More studies are needed. Future studies should include: 1. adult participants; 2. a wider variety of stimulant and non‐stimulant drugs, such as amphetamines and atomoxetine, respectively; and 3. additional important outcomes, such as seizure‐related hospitalisations and quality of life. Clusters of studies which assess the same drug – and those that build upon the evidence base presented in this review on OROS‐MPH and omega‐3 – are needed to allow for meta‐analysis of outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013136-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013136-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013136-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013136-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013136-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013136-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD013136-abs-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013136-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013136-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013136-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013136-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013136-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013136-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013136-abs-0002" lang="en"> <h3>Stimulant and non‐stimulant drug therapy for people with Attention Deficit Hyperactivity Disorder and epilepsy </h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out if stimulant and non‐stimulant medications are effective and safe in treating people with both Attention Deficit Hyperactivity Disorder (ADHD) and epilepsy. Cochrane Review authors collected and analysed all relevant studies to answer this question. </p> <p><b>Background</b> </p> <p>Epilepsy is a disease where the brain is predisposed to generating seizures. ADHD is a condition where daily life is affected by inattention, hyperactivity and impulsivity. It is common for a person with epilepsy to also have a diagnosis of ADHD. Both these diagnoses together can have a negative impact on education, occupation and family and social relationships. </p> <p>ADHD can be managed with drug therapy. This consists of stimulant drugs such as methylphenidate and non‐stimulant drugs such as atomoxetine. These drugs act on different neurotransmitters within the brain to improve concentration and impulse control. It is suggested that stimulant drugs, particularly methylphenidate, may aggravate epilepsy or cause seizures. Both stimulant and non‐stimulant drugs continue to be prescribed with a warning that they might worsen seizures. </p> <p>We do not know if stimulant and non‐stimulant drugs are effective and safe in treating people with ADHD and epilepsy. We also do not know if these drugs have intolerable side effects that stop people from taking them daily. </p> <p><b>What are the main results of the review?</b> </p> <p>We found two relevant studies involving children with both ADHD and epilepsy: one American study looked at osmotic‐release oral system methylphenidate (OROS‐MPH) and was funded by a government grant; one Iranian study looked at omega‐3 and was funded by a university grant. </p> <p>In the first study, children at an American outpatient clinic received either OROS‐MPH of increasingly higher doses or placebo. This study suggests that children receiving OROS‐MPH: </p> <p>• may have an increased risk of seizures with higher doses of OROS‐MPH, although we are not certain of this. </p> <p>• are probably twice as likely to stop taking OROS‐MPH due to side effects (e.g. worsening emotional lability and seizures), although we are only moderately confident in this result. </p> <p>• may improve their ADHD symptoms, although we are not certain of this.</p> <p>In the second study, children at an Iranian outpatient clinic received either omega‐3, the anti‐psychotic drug risperidone and usual anti‐seizure medication (ASM) or risperidone and usual ASM only. This study suggests that children receiving omega‐3: </p> <p>• may have fewer seizures (children who received omega‐3 had six or seven fewer seizures per month on average compared to children who did not receive omega‐3), although we are not certain of this. </p> <p>• may be less likely to stop taking omega‐3 due to side effects (sleepiness, diarrhoea and nausea and vomiting), although we are uncertain of this. However, the effects of omega‐3 vary, and it is possible that omega‐3 makes little or no difference. </p> <p>The review authors did not find any studies that looked at the effect of omega‐3 on ADHD symptoms.<br/>The review authors did not find any studies that looked at adults with ADHD and epilepsy, and other types of stimulant and non‐stimulant medication. </p> <p><b>Key messages</b> </p> <p>The stimulant drug OROS‐MPH may improve ADHD symptoms but may also increase the risk of adverse events such as seizures and emotional lability. The non‐stimulant drug omega‐3 may be safe to be used by children with both ADHD and epilepsy; however, we do not know if it is effective in treating the symptoms of ADHD. These conclusions should be interpreted with caution due to study biases, indirect outcome measures, small numbers of events and large confidence intervals. We still need more high‐quality studies including studies involving adults with both ADHD and epilepsy and more types of stimulant and non‐stimulant medications. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to October 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013136-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013136-sec-0092"></div> <h3 class="title" id="CD013136-sec-0093">Implications for practice</h3> <section id="CD013136-sec-0093"> <p>Preliminary findings suggest that osmotic‐release oral system methylphenidate (OROS‐MPH) may reduce the severity of attention deficit hyperactivity disorder <i>(</i>ADHD) symptoms in children with a dual‐diagnosis of ADHD and epilepsy. However, it is also possible that OROS‐MPH may increase the risk of seizures and other adverse events (e.g. worsened emotional lability) in this population. These conclusions should be interpreted with caution due to the low certainty surrounding the evidence used to inform them. There is also some preliminary evidence that the non‐stimulant drug omega‐3, administered in tandem with risperidone and the participant's usual regimen of AEDs, may reduce seizure frequency in children with a dual‐diagnosis of ADHD and epilepsy relative to risperidone and AEDs alone, although there is low certainty in this finding. It is also unclear whether this drug increases or decreases the risk of adverse events. Ultimately, more randomised controlled trials are needed to provide a more robust evidence base to better inform clinical practice about the safety and efficacy of stimulant and non‐stimulant drugs in people with a dual‐diagnosis of ADHD and epilepsy. </p> </section> <h3 class="title" id="CD013136-sec-0094">Implications for research</h3> <section id="CD013136-sec-0094"> <p>There is a dearth of randomised controlled trials exploring the efficacy and safety of stimulant and non‐stimulant drugs for people with a dual‐diagnosis of ADHD and epilepsy. More studies are needed. Future studies should include adult participants, as research to date has focused on children. A wider variety of stimulant and non‐stimulant drugs needs to be assessed, for example, amphetamines (stimulants) and clonidine (non‐stimulant), particularly those which are most commonly used in clinical practice to treat ADHD, such as the non‐stimulant atomoxetine. In addition, clusters of studies which assess the same drug are needed, in order to potentially allow for meta‐analysis of outcomes. To build on the evidence base presented in this review, future studies could focus on OROS‐MPH and omega‐3 fish oil. Important outcomes such as occurrence of status epilepticus episodes, seizure‐related hospitalisations, cognitive changes, changes in general behaviour and changes in quality of life scores need to be explored. Analysis of any change in seizure frequency should always be relative to baseline. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013136-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013136-sec-0008"></div> <div class="table" id="CD013136-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Osmotic‐release oral system methylphenidate compared to placebo for people with ADHD and epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Osmotic‐release oral system methylphenidate compared to control for people with ADHD and epilepsy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ADHD and epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> osmotic‐release oral system methylphenidate (OROS‐MPH) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OROS‐MPH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In logistic regression models calculating the odds of a seizure, significant predictors included the number of days of exposure to placebo or OROS‐MPH (P &lt; 0.005), the drug dose (P &lt; 0.005) and the interaction between them (P = 0.002 when drug dose examined as mg/kg/day and P &lt; 0.001 when examined as absolute dose). Cox proportional hazard models exploring time to seizure and hazard at each dose found that a higher mg/kg/day dose predicted a greater hazard of a seizure (P &lt; 0.001). Days of exposure was not significant, but the interaction between days of exposure and dose was (P &lt; 0.05). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people withdrawing from treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000<br/>(173 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.80<br/>(1.14 to 6.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No participant experienced significant worsening of epilepsy in either the OROS‐MPH or the placebo arm. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing 50% or greater reduction in seizure frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Descriptively, a greater proportion of participants received 'much improved' or 'very much improved' scores for ADHD symptoms on the CGI‐ADHD‐I in the OROS‐MPH arm relative to the placebo arm. Total ADHD‐RS score dropped across both the OROS‐MPH and placebo arms (week of treatment, P &lt; 0.0001), but dropped more rapidly in the OROS‐MPH arm (significant interaction between week of treatment and OROS‐MPH/placebo arm, P &lt; 0.0001). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing adverse drug events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No participants in either the OROS‐MPH or placebo arm experienced serious adverse events. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>ADHD: attention deficit hyperactivity disorder; ADHD‐RS: attention hyperactivity disorder‐rating scale; CGI‐ADHD‐I: Clinical Global Impressions for ADHD—Improvement; CI: confidence interval; OROS‐MPH: osmotic‐release oral system methylphenidate; RCT: randomised controlled trial; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>High certainty: Further research is very unlikely to change our confidence in the estimate of effect.<br/>Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/>Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/>Very low certainty: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: downgraded by one level. This study was rated 'unclear' for random sequence generation and allocation concealment, as well as high for other bias ‐ several authors received funding from McNeil Consumer Health, the provider of active OROS methylphenidate and matching placebo for this study.<br/><sup>b</sup>Indirectness: downgraded by one level. This study did not explore seizure frequency (change from baseline) as an outcome; instead it explored measures of seizure risk (the odds of a seizure on each day of exposure and the number of days of exposure until a seizure occurred).<br/><sup>c</sup>Indirectness: downgraded by one level. This study did not explore seizure severity (change from baseline) as a continuous outcome; instead, seizure severity formed part of the dichotomous outcome 'worsening of epilepsy'. This was defined as (1) a doubling of the highest 14‐day or highest 2‐day seizure rate observed during the 12 months before the trial, (2) a generalised tonic– clonic seizure if none had been experienced in the previous 2 years, or (3) a clinically meaningful intensification in seizure duration or severity.<br/><sup>d</sup>Indirectness: downgraded by one level. This study does not present the exact proportion of participants showing improvement in ADHD symptoms, or exact numbers for the change in total ADHD‐RS score. Data are provided in figures, preventing accurate estimates and therefore precluding risk ratio and mean difference calculations in this review. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013136-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ADHD and epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> omega‐3 (with risperidone and previous ASM) </p> <p><b>Comparison:</b> risperidone and previous ASM only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with risperidone &amp; ASM only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omega‐3 (with risperidone &amp; ASM)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure frequency (monthly, postintervention) <br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean seizure frequency was 17 seizures per month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.6 seizures per month lower<br/>(8.96 lower to 4.24 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of individuals withdrawing from treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(12 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/>(0.12 to 3.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline)<br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/>(93 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.79<br/>(0.84 to 9.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing adverse drug events<br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/>(65 to 655) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(0.44 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>ADHD: attention deficit hyperactivity disorder; ASM: anti‐seizure medication; CI: Confidence interval; MD: Mean difference; RCT: randomised controlled trial; RR: Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>High certainty: Further research is very unlikely to change our confidence in the estimate of effect.<br/>Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/>Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/>Very low certainty: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: downgraded by one level. Study rated as high risk of bias for 'blinding of participants and study personnel' and 'incomplete outcome data'.<br/><sup>b</sup>Imprecision: downgraded by one level. Statistical analysis was not paired between baseline and end‐of‐study outcome.<br/><sup>c</sup>Imprecision: downgraded by one level. Only a small number of adverse events occurred, and confidence intervals for the effect on adverse events are consistent with both and appreciable benefit and appreciable harm, so we lowered the certainty.<br/><sup>d</sup>Imprecision: downgraded by one level. Five participants who were randomised were excluded from analyses. Best‐and‐worst‐case sensitivity analyses which made assumptions about 50% or greater reduction in seizure frequency in these participants provided mixed results: confidence intervals of risk ratios suggested both an increase and decrease in the likelihood of 50% or greater reduction.<br/><sup>e</sup>Imprecision: downgraded by one level. Only a small number of adverse events occurred and confidence intervals for the effect on adverse events are consistent with both an appreciable benefit and appreciable harm, so we lowered the certainty. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013136-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013136-sec-0009"></div> <p>Epilepsy is defined as "a disease of the brain characterised by an enduring predisposition to generate epileptic seizures, and by the neurobiologic, cognitive, psychologic, and social consequences of this disease" (<a href="./references#CD013136-bbs2-0039" title="FisherR . Epilepsy: a new definition; 2014. Available at: www.epilepsy.com/article/2014/4/revised-definition-epilepsy.">Fisher 2014a</a>). Living with epilepsy can have devastating effects on health and lifestyle, particularly as seizures are associated with increased risk of death, serious injuries, depression, stigma, unemployment, and social exclusion (<a href="./references#CD013136-bbs2-0065" title="MlinarS , PetekD , CoticZ , Mencin CeplakM , ZaletelM . Persons with epilepsy: between social inclusion and marginalisation. Behavioural Neurology2016;2016:2018509. [PMID: 27212802]">Mlinar 2016</a>; <a href="./references#CD013136-bbs2-0086" title="SanderJW , Rugg-GunnFJ , SmallsJC , editor(s). Epilepsy 2009: From Benchside to Bedside - a Practical Guide to Epilepsy. 12th edition. National Society for Epilepsy, 2009. [ISBN: 978-0951955260]">Sander 2009</a>). Anti‐seizure medication (ASM) should not only reduce seizure frequency, but should also be tolerable in terms of adverse effects. The drugs used to treat co‐occurring conditions managed alongside epilepsy should, ideally, not lower seizure threshold or interact with ASM (<a href="./references#CD013136-bbs2-0023" title="CardamoneL , SalzbergMR , O'BrienTJ , JonesNC . Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?British Journal of Pharmacology2013;168(7):1531-54. [PMID: 23146067]">Cardamone 2013</a>). Attention Deficit Hyperactivity Disorder (ADHD) can co‐occur with epilepsy in 23% of the epilepsy population (<a href="./references#CD013136-bbs2-0083" title="RussSA , LarsonK , HalfonN . A national profile of childhood epilepsy and seizure disorder. Pediatrics2012;129(2):256-64. [PMID: 22271699]">Russ 2012</a>), and people with epilepsy have a 3.5‐fold increased risk of ADHD compared to people without epilepsy (<a href="./references#CD013136-bbs2-0021" title="BrikellI , GhirardiL , D'OnofrioBM , DunnDW , AlmqvistC , DalsgaardS , et al. Familial liability to epilepsy and attention-deficit/hyperactivity disorder: a nationwide cohort study. Biological Psychiatry2018;83(2):173-180. [DOI: 10.1016/j.biopsych.2017.08.006] [PMID: 28950988]">Brikell 2018</a>). This review examines the effect of stimulant and non‐stimulant drug treatment in adults and children with ADHD and co‐occurring epilepsy, in terms of the symptoms of ADHD, seizure frequency, seizure severity, adverse effects, and drug withdrawal. </p> <section id="CD013136-sec-0010"> <h3 class="title" id="CD013136-sec-0010">Description of the condition</h3> <p>Epilepsy is one of the most common neurologic diseases worldwide, affecting 70 million people and contributing to 0.7% of the global burden of disease (<a href="./references#CD013136-bbs2-0066" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2197-223. [PMID: 23245608]">Murray 2012</a>). It is defined as having two or more unprovoked seizures and is further classified by the International League Against Epilepsy (ILAE) according to seizure and epilepsy type (<a href="./references#CD013136-bbs2-0041" title="FisherRS , CrossJH , FrenchJA , HigurashiN , HirschE , JansenFE , et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia2017;58(4):522-30. [PMID: 28276060]">Fisher 2017</a>; <a href="./references#CD013136-bbs2-0089" title="SchefferIE , BerkovicS , CapovillaG , ConnollyMB , FrenchJ , GuilhotoL , et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia2017;58(4):512-21. [PMID: 28276062]">Scheffer 2017</a>). The incidence of epilepsy is 50 per 100,000 people per year in high‐income countries (defined as countries with an annual gross national income (GNI) per capita of USD 12,476 or more) (<a href="./references#CD013136-bbs2-0100" title="World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups2018.">World Bank 2018</a>). This rises to somewhere between 100 and 190 per 100,000 people per year in lower‐ and middle‐income countries (defined as countries with an annual GNI of USD 1025 or less, and USD 1026 to USD 12,475, respectively) (<a href="./references#CD013136-bbs2-0085" title="Sander, JW. The epidemiology of epilepsy revisited. Current Opinion in Neurology2003;16(2):165-70. [PMID: 12644744]">Sander 2003</a>; <a href="./references#CD013136-bbs2-0100" title="World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups2018.">World Bank 2018</a>). The prevalence of epilepsy in high‐income countries is 5.8 per 1000 people, and between 10.3 and 15.4 per 1000 people for low‐ and middle‐income countries (<a href="./references#CD013136-bbs2-0068" title="NgugiAK , BottomleyC , KleinschmidtI , SanderJW , NewtonCR . Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia2010;51(5):883-90. [PMID: 20067507]">Ngugi 2010</a>). In the majority of cases (60% to 75%), the cause of epilepsy is unknown. However, it is increasingly being recognised, with more modern classification systems, that a proportion of the unknown causes are probably genetic in nature with complex inheritance patterns and single‐gene mutations on susceptibility alleles (a component of a gene making it more likely that one will develop certain medical diseases) (<a href="./references#CD013136-bbs2-0036" title="SchachterSC , ShaferP , SirvenJ . Who gets epilepsy?Available at www.epilepsy.com/learn/epilepsy-101/who-gets-epilepsy2013.">Epilepsy Foundation 2013</a>; <a href="./references#CD013136-bbs2-0072" title="OttmanR . Analysis of genetically complex epilepsies. Epilepsia2005;46(Suppl 10):7-14. [PMID: 16359464]">Ottman 2005</a>). In cases where the cause of epilepsy is known, there is normally an association with the age of onset of epilepsy, of which there are two peak ages of onset. The first peak occurs in the early years of life, particularly at less than 10 years of age. This early peak is in close association with the incidence of birth defect‐related complications, perinatal (birth) complications, and infections. The incidence of epilepsy then peaks again in the sixth decade of life, due to the increased incidence of secondary changes in brain structure, led by cerebrovascular diseases and brain tumours (<a href="./references#CD013136-bbs2-0036" title="SchachterSC , ShaferP , SirvenJ . Who gets epilepsy?Available at www.epilepsy.com/learn/epilepsy-101/who-gets-epilepsy2013.">Epilepsy Foundation 2013</a>; <a href="./references#CD013136-bbs2-0085" title="Sander, JW. The epidemiology of epilepsy revisited. Current Opinion in Neurology2003;16(2):165-70. [PMID: 12644744]">Sander 2003</a>). </p> <p>Epilepsy and ADHD often co‐occur. ADHD is a condition characterised by inattention, hyperactivity and impulsivity to such an extent that function or development is impaired, and activities of daily life interfered with (<a href="./references#CD013136-bbs2-0034" title="American Psychiatric Association. DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association, 2013. [ISBN: ‎ 978-0890425558]">DSM‐V</a>; <a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a>; <a href="./references#CD013136-bbs2-0071" title="National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder; 2016. Available at: www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd#part_145444.">NIMH 2016</a>). The most established diagnostic classification systems for ADHD are the <i>International Classification of Diseases, 10<sup>th</sup> Revision</i> (<a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a>) and the <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</i> (DSM‐5) (<a href="./references#CD013136-bbs2-0034" title="American Psychiatric Association. DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association, 2013. [ISBN: ‎ 978-0890425558]">DSM‐V</a>; <a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a>). These classification systems recognise 18 symptoms indicative of inattention, hyperactivity and impulsivity. The criteria of the <a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a> and the <a href="./references#CD013136-bbs2-0034" title="American Psychiatric Association. DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association, 2013. [ISBN: ‎ 978-0890425558]">DSM‐V</a> require that inattention, hyperactivity and impulsivity are pervasive (i.e. present in a range of situations for at least six months) and present before six years (<a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a>), or 12 years of age (<a href="./references#CD013136-bbs2-0034" title="American Psychiatric Association. DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association, 2013. [ISBN: ‎ 978-0890425558]">DSM‐V</a>). Some impairments resulting from these symptoms should be observed in two or more settings, and there should also be impairment in social, academic or occupational functioning (<a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a>; <a href="./references#CD013136-bbs2-0033" title="American Psychiatric Association. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders Text Revision. 4th edition. Washington, DC: American Psychiatric Association, 2000. [ISBN: 978-0890420256]">DSM‐IV‐TR</a>; <a href="./references#CD013136-bbs2-0034" title="American Psychiatric Association. DSM-V: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association, 2013. [ISBN: ‎ 978-0890425558]">DSM‐V</a>; <a href="./references#CD013136-bbs2-0053" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. [ISBN: 9241544228] [URL: apps.who.int/iris/handle/10665/37958]">ICD‐10 1992</a>). Research has identified the cognitive difficulties to be broader than attention and to include executive functions, memory and self‐regulation difficulties (<a href="./references#CD013136-bbs2-0025" title="CoghillDR , SethS , PedrosoS , UsalaT , CurrieJ , GaglianoA . Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biological Psychiatry2014;76(8):603-15. [DOI: 10.1016/j.biopsych.2013.10.005] [PMID: 24231201]">Coghill 2014</a>; <a href="./references#CD013136-bbs2-0078" title="RhodesSM , CoghillDR , MatthewsKM . Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. Psychopharmacology2004;175(3):319-330. [DOI: 10.1007/s00213-004-1833-7] [PMID: 15138760]">Rhodes 2004</a>; <a href="./references#CD013136-bbs2-0079" title="RhodesSM , CoghillDR , MatthewsK . Neuropsychological functioning in stimulant-naive boys with hyperkinetic disorder. Psychological Medicine2005;35(8):1109-20. [DOI: 10.1017/S0033291705004599] [PMID: 16116937]">Rhodes 2005</a>; <a href="./references#CD013136-bbs2-0081" title="RhodesSM , ParkJ , SethS , CoghillDR . A comprehensive investigation of memory impairment in attention deficit hyperactivity disorder and oppositional defiant disorder. Journal of Child Psychology and Psychiatry, and Allied Disciplines2012;53(2):128-37. [DOI: 10.1111/j.1469-7610.2011.02436.x] [PMID: 21770938]">Rhodes 2012</a>). The diagnostic process should include an assessment of needs, co‐existing conditions, social, familial and educational or occupational circumstances, and physical health (<a href="./references#CD013136-bbs2-0070" title="National Institue for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. www.nice.org.uk/guidance/ng872008. [NICE GUIDELINE: NG87]">NICE 2008</a>). The cause(s) of ADHD are not known. However, there are possible correlations with abnormalities in brain structure or function, genetic involvement, and pre‐ or postnatal environmental risks such as maternal cigarette smoking and the early parent‐child relationship, respectively (<a href="./references#CD013136-bbs2-0056" title="KaufmannR , Goldberg-SternH , ShuperA . Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Journal of Child Neurology2009;24(6):727-33. [PMID: 19491115]">Kaufmann 2009</a>; <a href="./references#CD013136-bbs2-0069" title="NHS Choices. Attention deficit hyperactivity disorder (ADHD) — causes. www.nhs.uk/Conditions/Attention-deficit-hyperactivity-disorder/Pages/Causes.aspx2016.">NHS 2016</a>; <a href="./references#CD013136-bbs2-0095" title="ThaparA , CooperM , EyreO , LangleyK . What have we learnt about the causes of ADHD?Journal of Child Psychology and Psychiatry, and Allied Disciplines2013;54(1):3-16. [PMID: 22963644]">Thapar 2013</a>). </p> <p>Symptoms of ADHD are normally present at the time of, or before, someone's first seizure. This suggests that ADHD is a co‐occurring condition rather than a condition caused by the seizure disorder or its treatments (<a href="./references#CD013136-bbs2-0050" title="HesdorfferDC , LudvigssonP , OlafssonE , GudmundssonG , KjartanssonO , HauserWA . ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Archives of General Psychiatry2004;61(7):731-6. [PMID: 15237085]">Hesdorffer 2004</a>; <a href="./references#CD013136-bbs2-0099" title="WilliamsAE , GiustJM , KronenbergerWG , DunnDW . Epilepsy and attention-deficit hyperactivity disorder: links, risks and challenges. Neuropsychiatric Disease and Treatment2016;12:287-96. [PMID: 26929624]">Williams 2016</a>). Co‐occurring ADHD and epilepsy continue into adolescence and adulthood in around two‐thirds of patients. Together, they have an increasingly negative impact on academic achievement, occupational status, as well as social and family relationships (<a href="./references#CD013136-bbs2-0024" title="Centers for Disease Prevention and Control. Data and Statistics About ADHD. www.cdc.gov/ncbddd/adhd/data.html2017.">CDC 2017</a>; <a href="./references#CD013136-bbs2-0067" title="National Alliance on Mental Illness. Attention deficit hyperactivity disorder (ADHD). Available at: www.nami.org/Learn-More/Mental-Health-Conditions/ADHD; 2017.">National Alliance on Mental Illness 2017</a>; <a href="./references#CD013136-bbs2-0075" title="RadziukAL , KielingRR , SantosK , RotertR , BastosF , PalminiAL . Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy &amp; Behaviour2015;46:215-20. [PMID: 25940104]">Radziuk 2015</a>). The prevalence of ADHD in the paediatric epilepsy population is as high as 23% to 40% (<a href="./references#CD013136-bbs2-0026" title="CohenR , SeneckyY , ShuperA , InbarD , ChodickG , ShalevV , et al. Prevalence of epilepsy and attention-deficit hyperactivity disorder (ADHD): a population-based study. Journal of Child Neurology2013;28(1):120-3. [PMID: 22550087]">Cohen 2013</a>; <a href="./references#CD013136-bbs2-0083" title="RussSA , LarsonK , HalfonN . A national profile of childhood epilepsy and seizure disorder. Pediatrics2012;129(2):256-64. [PMID: 22271699]">Russ 2012</a>), compared with a prevalence rate of between 2% and 8% in the non‐epileptic control population, depending on the country studied (<a href="./references#CD013136-bbs2-0030" title="CzamaraD , TieslerCM , KohlböckG , BerdelD , HoffmannB , BauerCP , et al. Children with ADHD symptoms have a higher risk for reading, spelling and math difficulties in the GINIplus and LISAplus cohort studies. PLoS One2013;8(5):e63859. [DOI: 10.1371/journal.pone.0063859] [PMID: 23724008]">Czamara 2013</a>; <a href="./references#CD013136-bbs2-0062" title="MarcusDK , NorrisAL , CoccaroEF . The latent structure of attention deficit/hyperactivity disorder in an adult sample. Journal of Psychiatric Research2012;46(6):782-9. [DOI: 10.1016/j.jpsychires.2012.03.010] [PMID: 22480749]">Marcus 2012</a>; <a href="./references#CD013136-bbs2-0084" title="RussellG , RodgersLR , UkoumunneOC , FordT . Prevalence of parent-reported ASD and ADHD in the UK: findings from the Millennium Cohort Study. Journal of Autism and Developmental Disorders2014;44(1):31-40. [DOI: 10.1007/s10803-013-1849-0] [PMID: 23719853]">Russell 2014</a>), with a worldwide average of around 5% (<a href="./references#CD013136-bbs2-0074" title="PolanczykG , deLimaMS , HortaBL , BidermanJ , RohdeLA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry2007;164:942-8. [DOI: 10.1176/ajp.2007.164.6.942] [PMID: 17541055]">Polanczyk 2007</a>; <a href="./references#CD013136-bbs2-0088" title="SayalK , PrasadV , DaleyD , FordT , CoghillD . ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry2018;5(2):175-86. [DOI: 10.1016/S2215-0366(17)30167-0] [PMID: 29033005]">Sayal  2018</a>). In the adult population, the prevalence of ADHD is 4% (<a href="./references#CD013136-bbs2-0067" title="National Alliance on Mental Illness. Attention deficit hyperactivity disorder (ADHD). Available at: www.nami.org/Learn-More/Mental-Health-Conditions/ADHD; 2017.">National Alliance on Mental Illness 2017</a>), and the prevalence of epilepsy ranges from 4 to 10 per 1000 people (<a href="./references#CD013136-bbs2-0073" title="PicotMC , Baldy-MoulinierM , DaurèsJP , DujolsP , CrespelA . The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia2008;49(7):1230-8. [PMID: 18363709]">Picot 2008</a>). There are several proposed mechanisms for the high prevalence of ADHD in the epilepsy population. These include a common genetic propensity, adrenergic system dysfunction causing both epilepsy and ADHD, and psychosocial risk factors. Furthermore, people with ADHD have a higher‐than‐normal rate of electroencephalogram (EEG) abnormalities, even without a history of epilepsy. Such epileptiform discharges are associated with cognitive impairment and manifestation of ADHD symptoms such that in some cases, ASM use may not only abolish epileptiform discharges, but also improve ADHD symptoms (<a href="./references#CD013136-bbs2-0056" title="KaufmannR , Goldberg-SternH , ShuperA . Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Journal of Child Neurology2009;24(6):727-33. [PMID: 19491115]">Kaufmann 2009</a>). </p> <p>There are some subtle differences between ADHD in children and adults. Hyperactivity ‐ but not impulsivity ‐ seems to become a less evident component of the disorder in adults. Impulsivity may be a distinct source of impairment compared to hyperactivity in adults (<a href="./references#CD013136-bbs2-0064" title="MartelMM , vonEyeA , NiggJ . Developmental differences in structure of attention-deficit/hyperactivity disorder (ADHD) between childhood and adulthood. International Journal of Behavioral Development2012;36(4):279-92. [PMID: 25635150]">Martel 2012</a>). This may change how the disease causes impairment and how it is managed between children and adults. The impact of seizures and their underlying abnormal neural substrate are different in the developing paediatric brain and the mature adult brain such that there may be contrasting patterns of neuropsychological performance in children and adults with epilepsy (<a href="./references#CD013136-bbs2-0093" title="SmithML . Neuropsychology in epilepsy: children are not small adults. Epilepsia2010;51(Suppl 1):68-9. [PMID: 20331721]">Smith 2010</a>). This may differentially confound the phenotype of ADHD in children and adults with epilepsy such that subgroup analysis of outcomes between these two groups following treatment may be helpful. </p> </section> <section id="CD013136-sec-0011"> <h3 class="title" id="CD013136-sec-0011">Description of the intervention</h3> <p>Drug therapy in ADHD should form part of a wider treatment programme that includes lifestyle support. Psychological interventions should be offered to all children with ADHD. In children with moderate symptoms of ADHD, drug therapy should be used when psychological interventions have been unsuccessful or are unavailable (<a href="./references#CD013136-bbs2-0020" title="Joint Formulary Committee. BNF 73 (British National Formulary). London: Pharmaceutical Press, 2017. [ISBN: ‎ 978-0857112767]">BNF 2017</a>). In children with severe and persistent symptoms of ADHD, drug therapy should be commenced routinely alongside psychological interventions. Drug therapy for ADHD consists of central nervous system (CNS) stimulant and non‐stimulant drugs. Stimulant drugs include the amphetamines (e.g. dexamfetamine and lisdexamfetamine) and related drugs (e.g. methylphenidate). These drugs increase the action of dopamine in the basal ganglia and prefrontal cortex by preventing its reuptake. The drugs work by improving self‐regulation (<a href="./references#CD013136-bbs2-0080" title="RhodesSM , CoghillDR , MatthewsK . Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II — broader executive and non-executive domains. Journal of Child Psychology and Psychiatry, and Allied Disciplines2006;47(11):1184-94. [DOI: 10.1111/j.1469-7610.2006.01633.x] [PMID: 17076758]">Rhodes 2006</a>), memory (<a href="./references#CD013136-bbs2-0025" title="CoghillDR , SethS , PedrosoS , UsalaT , CurrieJ , GaglianoA . Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biological Psychiatry2014;76(8):603-15. [DOI: 10.1016/j.biopsych.2013.10.005] [PMID: 24231201]">Coghill 2014</a>; <a href="./references#CD013136-bbs2-0078" title="RhodesSM , CoghillDR , MatthewsKM . Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. Psychopharmacology2004;175(3):319-330. [DOI: 10.1007/s00213-004-1833-7] [PMID: 15138760]">Rhodes 2004</a>), and executive functions (<a href="./references#CD013136-bbs2-0031" title="De SousaA , KalraG . Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monographs2012;10(1):45-69. [PMID: 22654382]">De Sousa 2012</a>; <a href="./references#CD013136-bbs2-0043" title="GauSS , ShangCY . Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. International Journal of Neuropsychopharmacology2010;13(2):243-56. [DOI: 10.1017/S1461145709990836] [PMID: 19849892]">Gau 2010</a>; <a href="./references#CD013136-bbs2-0052" title="HosenbocusS , ChahalR . A review of executive function deficits and pharmacological management in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(3):223-9. [PMID: 22876270]">Hosenbocus 2012</a>; <a href="./references#CD013136-bbs2-0082" title="RosenauPT , OpenneerTJ , MatthijssenAM , vande Loo-NeusGH , BuitelaarJK , vanden HoofdakkerBJ , et al. Effects of methylphenidate on executive functioning in children and adolescents with ADHD after long-term use: a randomized, placebo-controlled discontinuation study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2021;62(12):1444-52. [DOI: 10.1111/jcpp.13419] [PMID: 33778945]">Rosenau 2021</a>). The basal ganglia are in charge of modifying motor control and determining when it is appropriate to perform an action. People with ADHD are believed to have dysfunctional basal ganglia. Therefore, increasing levels of dopamine, by drug therapy, allows the brain in ADHD to function more effectively (<a href="./references#CD013136-bbs2-0059" title="LeismanG , Braun-BenjaminO , MelilloR . Cognitive-motor interactions of the basal ganglia in development. Frontiers in Systems Neuroscience2014;8:16. [PMID: 24592214]">Leisman 2014</a>). Adverse effects related to stimulant drugs are primarily insomnia, irritability, gastrointestinal discomfort or nausea, as well as increases in heart rate and blood pressure (<a href="./references#CD013136-bbs2-0020" title="Joint Formulary Committee. BNF 73 (British National Formulary). London: Pharmaceutical Press, 2017. [ISBN: ‎ 978-0857112767]">BNF 2017</a>). Non‐stimulant drugs include atomoxetine, clonidine, guanfacine, lofexidine, and bupropion (<a href="./references#CD013136-bbs2-0022" title="BrownMG , BeckerDA , PollardJR , AndersonCT . The diagnosis and treatment of attention deficit hyperactivity disorder in patients with epilepsy. Current Neurology and Neuroscience Reports2013;13(6):351. [PMID: 23636930]">Brown 2013</a>); the most widely used is atomoxetine. Atomoxetine works as a selective noradrenaline reuptake inhibitor, increasing levels of dopamine and noradrenaline in the prefrontal cortex; it has less of an effect in the basal ganglia (<a href="./references#CD013136-bbs2-0092" title="ShierAC , ReichenbacherT , GhumanHS , GhumanJK . Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. Journal of Central Nervous System Disease2012;5:1-17. [PMID: 23650474]">Shier 2013</a>). </p> <p>The choice of drug in ADHD therapy should take into account the drug's effect on a person's comorbidities. Comorbidities commonly seen with ADHD include Autistic Spectrum Disorder, Developmental Coordination Disorder/dyspraxia, tic disorders, Tourette's syndrome, and epilepsy (<a href="./references#CD013136-bbs2-0045" title="GnanavelS , SharmaP , KaushalP , HussainS . Attention deficit hyperactivity disorder and comorbidity: a review of literature. World Journal of Clinical Cases2019;7(17):2420-6. [DOI: 10.12998/wjcc.v7.i17.2420] [PMID: 31559278]">Gnanavel 2019</a>; <a href="./references#CD013136-bbs2-0046" title="GoulardinsJB , RigoliD , LicariM , PiekJP , HasueRH , OosterlaanJ , et al. Attention deficit hyperactivity disorder and developmental coordination disorder: two separate disorders or do they share a common etiology. Behavioural Brain Research2015;292:484-92. [DOI: 10.1016/j.bbr.2015.07.009] [PMID: 26168770]">Goulardins 2015</a>; <a href="./references#CD013136-bbs2-0060" title="LeitnerY . The co-occurrence of autism and attention deficit hyperactivity disorder in children — what do we know?Frontiers in Human Neuroscience2014;8:268. [DOI: 10.3389/fnhum.2014.00268] [PMID: 24808851]">Leitner 2014</a>; <a href="./references#CD013136-bbs2-0083" title="RussSA , LarsonK , HalfonN . A national profile of childhood epilepsy and seizure disorder. Pediatrics2012;129(2):256-64. [PMID: 22271699]">Russ 2012</a>). The choice of ADHD drug should also be influenced by its adverse effect profile, potential for drug misuse, tolerance and dependence, as well as patient/carer preference (<a href="./references#CD013136-bbs2-0020" title="Joint Formulary Committee. BNF 73 (British National Formulary). London: Pharmaceutical Press, 2017. [ISBN: ‎ 978-0857112767]">BNF 2017</a>). The National Institute for Health and Care Excellence (NICE) recommend the following choices for drug therapy in children with ADHD: </p> <p> <ol id="CD013136-list-0001"> <li> <p>methylphenidate for ADHD without significant comorbidity;</p> </li> <li> <p>methylphenidate for ADHD with comorbid conduct disorder (severe behavioural problems);</p> </li> <li> <p>methylphenidate or atomoxetine when tics, Tourette's syndrome, anxiety disorder, stimulant misuse or risk of stimulant diversion are present; </p> </li> <li> <p>atomoxetine if methylphenidate has been tried and has been ineffective at the maximum tolerated dose, or the child is intolerant to low or moderate doses of methylphenidate (<a href="./references#CD013136-bbs2-0070" title="National Institue for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. www.nice.org.uk/guidance/ng872008. [NICE GUIDELINE: NG87]">NICE 2008</a>). </p> </li> </ol> </p> <p>For adults with ADHD, NICE recommends that methylphenidate should be tried first. Atomoxetine or dexamfetamine are recommended if symptoms do not respond to methylphenidate or the person is intolerant to it after an adequate trial (approximately six weeks). Atomoxetine should be the first‐line choice if there are concerns about drug misuse (<a href="./references#CD013136-bbs2-0070" title="National Institue for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. www.nice.org.uk/guidance/ng872008. [NICE GUIDELINE: NG87]">NICE 2008</a>). </p> <p>In the context of ADHD and epilepsy, the recommendation is that if seizures are exacerbated or new seizures emerge following the introduction of methylphenidate or atomoxetine, the drug should be discontinued immediately. Dexamfetamine may be considered as an alternative in consultation with a regional tertiary specialist treatment centre (<a href="./references#CD013136-bbs2-0070" title="National Institue for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. www.nice.org.uk/guidance/ng872008. [NICE GUIDELINE: NG87]">NICE 2008</a>). </p> </section> <section id="CD013136-sec-0012"> <h3 class="title" id="CD013136-sec-0012">How the intervention might work</h3> <p>Stimulant drugs are able to bypass the blood‐brain barrier and work by increasing the level of catecholamines, dopamine and noradrenaline in both the peripheral and central nervous systems. Amphetamines can do this in a variety of ways. Firstly, they act as competitive inhibitors to the monoamine reuptake transporters (DAT and NET), reducing the reuptake of dopamine and noradrenaline into nerve terminals. Moreover, amphetamines enter the synaptic cleft (space between nerve endings) via diffusion or active reuptake. They then interact with vesicular monoamine pumps (VMAT‐2), which prevent the catecholamines present in the cytoplasm (material in a cell outside its nucleus) from being taken up into synaptic storage vesicles. Finally, at high concentrations, amphetamines can inhibit the action of monoamine oxidase (an enzyme), thereby preventing the breakdown of catecholamines (<a href="./references#CD013136-bbs2-0063" title="MarkowitzJS , PatrickKS . Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clinical Pharmacokinetics2001;40(10):753-72. [PMID: 11707061]">Markowitz 2001</a>; <a href="./references#CD013136-bbs2-0076" title="RangHP , DaleMM , RitterJ , FlowerRJ , HendersonG . CNS stimulants and psychotomimetic drugs. In: Rang and Dale's Pharmacology. 7th edition. Edinburgh; New York: Elsevier/Churchill Livingstone, 2011. [ISBN: 9780702034718]">Rang 2011</a>). </p> <p>Methylphenidate acts similarly to amphetamines, by inhibiting monoamine reuptake inhibitors, but it cannot enter nerve terminals. Therefore, it acts by producing a prolonged increase in catecholamines in the synaptic cleft (<a href="./references#CD013136-bbs2-0076" title="RangHP , DaleMM , RitterJ , FlowerRJ , HendersonG . CNS stimulants and psychotomimetic drugs. In: Rang and Dale's Pharmacology. 7th edition. Edinburgh; New York: Elsevier/Churchill Livingstone, 2011. [ISBN: 9780702034718]">Rang 2011</a>; <a href="./references#CD013136-bbs2-0063" title="MarkowitzJS , PatrickKS . Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clinical Pharmacokinetics2001;40(10):753-72. [PMID: 11707061]">Markowitz 2001</a>). </p> <p>Slow‐release formulations of these drugs are used in ADHD to prevent the euphoric side effects seen with stimulants. They are taken orally and absorbed through the gastrointestinal tract. Amphetamines are rapidly absorbed and have a half‐life that varies from five to 30 hours. They are metabolised primarily through deamination (the removal of an amino group from an amino acid) and converted into benzoic acid and hippuric acid in the kidneys before being excreted in urine. Methylphenidate is absorbed more slowly, and 80% is metabolised into ritalinic acid prior to entering the systemic circulation. The half‐life of methylphenidate is only two to four hours, and the 20% that enters the systemic circulation is metabolised by carboxylesterase (<a href="./references#CD013136-bbs2-0076" title="RangHP , DaleMM , RitterJ , FlowerRJ , HendersonG . CNS stimulants and psychotomimetic drugs. In: Rang and Dale's Pharmacology. 7th edition. Edinburgh; New York: Elsevier/Churchill Livingstone, 2011. [ISBN: 9780702034718]">Rang 2011</a>). </p> <p>Atomoxetine is a highly selective noradrenaline reuptake inhibitor and increases noradrenaline concentrations outside the cell. The drug is absorbed through the gastrointestinal tract and has a half‐life of anywhere from five to 22 hours. The half‐life is dependent on the activity of CYP2D6, which metabolises the drug. Atomoxetine is excreted through the kidneys (<a href="./references#CD013136-bbs2-0038" title="US Food and Drug Administration, Eli Lilly and Company. Strattera (atomoxetine HCl). Available at www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf; 2006.">FDA 2006</a>; <a href="./references#CD013136-bbs2-0076" title="RangHP , DaleMM , RitterJ , FlowerRJ , HendersonG . CNS stimulants and psychotomimetic drugs. In: Rang and Dale's Pharmacology. 7th edition. Edinburgh; New York: Elsevier/Churchill Livingstone, 2011. [ISBN: 9780702034718]">Rang 2011</a>). The pharmacokinetics (movements of the drug within the body) of atomoxetine are affected by concomitant use with paroxetine, which decreases its excretion and therefore results in an increased systemic concentration of atomoxetine (<a href="./references#CD013136-bbs2-0087" title="SauerJM , RingBJ , WitcherJW . Clinical pharmacokinetics of atomoxetine. Clinical Pharmacokinetics2005;44(6):571-90. [PMID: 15910008]">Sauer 2005</a>). </p> </section> <section id="CD013136-sec-0013"> <h3 class="title" id="CD013136-sec-0013">Why it is important to do this review</h3> <p>There is clinical debate about the efficacy and safety of stimulant and non‐stimulant drugs used to treat ADHD in people with co‐occurring epilepsy (<a href="./references#CD013136-bbs2-0031" title="De SousaA , KalraG . Drug therapy of attention deficit hyperactivity disorder: current trends. Mens Sana Monographs2012;10(1):45-69. [PMID: 22654382]">De Sousa 2012</a>). It is suggested that stimulant drugs, particularly methylphenidate, may induce new‐onset epilepsy, aggravate existing epilepsy, or lower the seizure threshold in people with epilepsy or an abnormal EEG (<a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>; <a href="./references#CD013136-bbs2-0055" title="KattimaniS , MahadevanS . Treating children with attention-deficit/hyperactivity disorder and comorbid epilepsy. Annals of Indian Academy of Neurology2011;14(1):9-11. [PMID: 21633607]">Kattimani 2011</a>). However, the mechanism of these possible effects is as yet undescribed and the aggravation of seizures, or the onset of new ones, may be a coincidental part of the normal course of the epileptic disease. Methylphenidate affects the presynaptic reuptake of noradrenaline and dopamine but has no effect on neurotransmitters such as gamma aminobutyric acid (GABA), glutamate and aspartic acid, or sodium and calcium channels, which are associated with the pathophysiology of epilepsy. Methylphenidate and the other stimulant drugs continue to be prescribed with a warning that they may increase seizures, and clinicians are advised to discontinue these drugs if seizure frequency increases (<a href="./references#CD013136-bbs2-0056" title="KaufmannR , Goldberg-SternH , ShuperA . Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Journal of Child Neurology2009;24(6):727-33. [PMID: 19491115]">Kaufmann 2009</a>). Methylphenidate is also thought to increase the plasma concentration of several ASM, including fosphenytoin, phenobarbital, phenytoin, and primidone (<a href="./references#CD013136-bbs2-0020" title="Joint Formulary Committee. BNF 73 (British National Formulary). London: Pharmaceutical Press, 2017. [ISBN: ‎ 978-0857112767]">BNF 2017</a>). Such interactions are a reason why older ASM are now less commonly used in clinical practice (<a href="./references#CD013136-bbs2-0042" title="FrenchJA , GazzolaDM . New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Therapeutic Advances in Drug Safety2011;2(4):141-58. [PMID: 25083209]">French 2011</a>). </p> <p>Atomoxetine has virtually no affinity for other transport mechanisms or receptors, including those implicated in the pathogenesis of epilepsy. Therefore, based on its chemistry and pharmacology, there is no reason to believe it to be epileptogenic. A recent review of the literature found that atomoxetine does not appear to increase the risk of seizures (<a href="./references#CD013136-bbs2-0099" title="WilliamsAE , GiustJM , KronenbergerWG , DunnDW . Epilepsy and attention-deficit hyperactivity disorder: links, risks and challenges. Neuropsychiatric Disease and Treatment2016;12:287-96. [PMID: 26929624]">Williams 2016</a>). However, atomoxetine continues to be prescribed with a warning that it may increase seizures, and clinicians are advised to discontinue the drug if seizure frequency increases (<a href="./references#CD013136-bbs2-0056" title="KaufmannR , Goldberg-SternH , ShuperA . Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Journal of Child Neurology2009;24(6):727-33. [PMID: 19491115]">Kaufmann 2009</a>). There are no reported interactions between ASM and atomoxetine (<a href="./references#CD013136-bbs2-0020" title="Joint Formulary Committee. BNF 73 (British National Formulary). London: Pharmaceutical Press, 2017. [ISBN: ‎ 978-0857112767]">BNF 2017</a>). </p> <p>ADHD is managed using stimulant and non‐stimulant drugs and, although there are warnings surrounding the use of these in ADHD and co‐occurring epilepsy, the evidence is conflicting and remains to be appraised in a systematic review and meta‐analysis (<a href="./references#CD013136-bbs2-0022" title="BrownMG , BeckerDA , PollardJR , AndersonCT . The diagnosis and treatment of attention deficit hyperactivity disorder in patients with epilepsy. Current Neurology and Neuroscience Reports2013;13(6):351. [PMID: 23636930]">Brown 2013</a>; <a href="./references#CD013136-bbs2-0056" title="KaufmannR , Goldberg-SternH , ShuperA . Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. Journal of Child Neurology2009;24(6):727-33. [PMID: 19491115]">Kaufmann 2009</a>). This review aims to address this gap in appraisal by systematically evaluating clinical trials of both stimulant and non‐stimulant drugs in people with ADHD and co‐occurring epilepsy. Outcomes of interest include seizure frequency and severity, symptoms of ADHD, adverse effects as well as drug withdrawal. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013136-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013136-sec-0014"></div> <p>To assess the effect of stimulant and non‐stimulant drugs on children and adults with ADHD and co‐occurring epilepsy in terms of seizure frequency and drug withdrawal rates (primary objectives), as well as seizure severity, ADHD symptoms, cognitive state, general behaviour, quality of life, and adverse effects profile (secondary objectives). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013136-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013136-sec-0015"></div> <section id="CD013136-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013136-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included studies that met the following criteria.</p> <p> <ol id="CD013136-list-0002"> <li> <p>Intervention studies (we excluded observational studies)</p> </li> <li> <p>Randomised control trials (RCTs): the trial was described by the study author(s) as a 'randomised controlled trial' (or words to that effect), or a process of random allocation into intervention groups was described. </p> </li> <li> <p>Placebo‐, active‐ or usual‐treatment controlled</p> </li> <li> <p>Double‐blind, single‐blind, or unblinded</p> </li> <li> <p>Parallel or cross‐over design</p> </li> </ol> </p> </section> <section id="CD013136-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants that met the following criteria.</p> <p> <ol id="CD013136-list-0003"> <li> <p>Any age, gender, ethnicity, and country</p> </li> <li> <p>A diagnosis of both ADHD, according to a recognised classification system such as the DSM or the ICD, and epilepsy. A diagnosis of epilepsy must have been stated, and we noted any particular classification system used. </p> </li> </ol> </p> </section> <section id="CD013136-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that reported testing the following interventions.</p> <p> <ol id="CD013136-list-0004"> <li> <p>The use of CNS stimulant drugs including, but not exclusively, the amphetamines (dexamfetamine and lisdexamfetamine) and related drugs (e.g. methylphenidate). </p> </li> <li> <p>The use of non‐stimulant CNS drugs including, but not exclusively, atomoxetine, clonidine, guanfacine, lofexadine, and bupropion. </p> </li> </ol> </p> <p>Trials with at least one of the following comparisons were eligible.</p> <p> <ol id="CD013136-list-0005"> <li> <p>Stimulant therapy versus control</p> </li> <li> <p>Non‐stimulant therapy versus control</p> </li> <li> <p>Stimulant therapy versus non‐stimulant therapy</p> </li> <li> <p>Stimulant therapy versus non‐stimulant therapy versus control</p> </li> <li> <p>Stimulant therapy 1 versus stimulant therapy 2</p> </li> <li> <p>Non‐stimulant therapy 1 versus non‐stimulant therapy 2</p> </li> </ol> </p> </section> <section id="CD013136-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013136-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013136-list-0006"> <li> <p>Seizure frequency (change from baseline)</p> </li> <li> <p>Proportion of people withdrawing from treatment</p> </li> </ol> </p> </section> <section id="CD013136-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013136-list-0007"> <li> <p>Seizure severity (change from baseline)</p> </li> <li> <p>Number of episodes of status epilepticus (change from baseline)</p> </li> <li> <p>Number of seizure‐related hospitalisations (change from baseline)</p> </li> <li> <p>Proportion of people achieving 50% or greater reduction in seizure frequency</p> </li> <li> <p>ADHD symptoms (change from baseline): attention, hyperactivity and impulsivity, measured by psychometric instruments or by observations of behaviour, using, for example, Conners’ Rating Scales (<a href="./references#CD013136-bbs2-0027" title="ConnersCK . Conners 3rd Edition. Toronto: Multi-Health Systems Inc, 2008.">Conners 2008</a>). Raters could be teachers, independent assessors or parents. </p> </li> <li> <p>Proportion of people experiencing adverse drug events</p> </li> <li> <p>Cognitive effects, as changes from baseline in scores on neuropsychological tests such as the Wechsler Adult Intelligence Scale (WAIS, <a href="./references#CD013136-bbs2-0098" title="WechslerD . WAIS-III: administration and scoring manual: Wechsler Adult Intelligence Scale. 3rd edition. San Antonio (TX): The Psychological Corporation, 1997. [ISBN: 9780158981031]">Wechsler 1997</a>), and the Wide Range Assessment of Memory and Learning‐2 (WRAML‐2, <a href="./references#CD013136-bbs2-0091" title="SheslowD , AdamsW . Wide Range Assessment of Memory and Learning, Second Edition (WRAML2); 2003. Available from: www.pearsonclinical.co.uk/Education/Assessments/memory-assessments/wraml2/wide-range-assessment-of-memory-and-learning-wraml2.aspx.">Sheslow 2003</a>). </p> </li> <li> <p>General behaviour effects, as changes from baseline in scores on psychometric instruments such as the Child Behaviour Checklist (CBCL; <a href="./references#CD013136-bbs2-0018" title="AchenbachTM . Manual for the Child Behavior Checklist/4-18 and 1991 Profile. Burlington, VT: Department of Psychiatry, University of Vermont, 1991. [ISBN: 9780938565086]">Achenbach 1991</a>). </p> </li> <li> <p>Quality of life (QoL) scores (change from baseline), as measured by psychometric instruments such as the Child Health Questionnaire (CHQ; <a href="./references#CD013136-bbs2-0057" title="LandgrafJM , MaunsellE , SpeechleyKN , BullingerM , CampbellS , AbetzL , et al. Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Quality of Life Research1998;7(5):433-45. [PMID: 9691723]">Landgraf 1998</a>), and Quality of Life in Epilepsy Inventory (QOLIE‐31, <a href="./references#CD013136-bbs2-0029" title="CramerJA , PerrineK , DevinskyO , Bryant-ComstockL , MeadorK , HermannB . Development and cross‐cultural translations of a 31‐item quality of life in epilepsy inventory. Epilepsia1998;39(1):81-8. [PMID: 9578017]">Cramer 1998</a>). Raters could be teachers, independent assessors or parents. </p> </li> </ol> </p> </section> </section> </section> <section id="CD013136-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013136-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 12 October 2020.</p> <p> <ol id="CD013136-list-0008"> <li> <p>Cochrane Register of Studies (CRS Web), using the search strategy shown in <a href="./appendices#CD013136-sec-0098">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid), 1946 to 9 October 2020, using the search strategy shown in <a href="./appendices#CD013136-sec-0099">Appendix 2</a>. </p> </li> <li> <p>CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature), 1937 onwards (EBSCOhost), using the search strategy shown in <a href="./appendices#CD013136-sec-0100">Appendix 3</a>. </p> </li> </ol> </p> <p>There were no language restrictions. CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialised Registers of Cochrane Review Groups including Epilepsy. In MEDLINE (Ovid) the coverage end date always lags a few days behind the search date. </p> </section> <section id="CD013136-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We identified other potentially eligible trials by searching the reference lists of included trials and any relevant reviews found. </p> </section> </section> <section id="CD013136-sec-0026"> <h3 class="title" id="CD013136-sec-0026">Data collection and analysis</h3> <section id="CD013136-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CE and KY) independently screened the titles and abstracts of papers to exclude any that were not relevant to the study. They then screened articles in full to remove any that were irrelevant or did not meet the inclusion criteria. Authors used the <a href="./references#CD013136-bbs2-0028" title="Covidence. Version accessed 2020. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> systematic review software for both title and abstract screening and full‐text review. For papers excluded at the full‐text stage, authors recorded their bibliographic data along with the reason(s) for exclusion. A third review author (RFMC) resolved any disagreements that arose. </p> </section> <section id="CD013136-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CE and KY) independently extracted the following information, where available, from published manuscripts. A third review author (RFMC) resolved any disagreements that arose. Authors extracted data using the Cochrane Effective Practice and Organisation of Care data collection form (<a href="./references#CD013136-bbs2-0037" title="Cochrane Effective Practice and Organisation of Care (EPOC). EPOC Resources for review authors: data collection form. epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/good_practice_data_extraction_form.doc2017.">EPOC 2017</a>). </p> <p> <ol id="CD013136-list-0009"> <li> <p><b>Publication details</b> </p> <ol id="CD013136-list-0010"> <li> <p>Author(s)</p> </li> <li> <p>Year of publication</p> </li> <li> <p>Funding source/type</p> </li> <li> <p>Whether a conflict of interest statement was made</p> </li> </ol> </li> <li> <p><b>Methodological/trial design</b> </p> <ol id="CD013136-list-0011"> <li> <p>Country(s) of study</p> </li> <li> <p>Type of study</p> </li> <li> <p>Study setting (e.g. inpatient or outpatient)</p> </li> <li> <p>Inclusion/exclusion criteria</p> </li> <li> <p>Length of recruitment period</p> </li> <li> <p>Method of randomisation (random sequence generation): authors extracted all reported information on the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> </li> <li> <p>Method of randomisation concealment (allocation concealment): authors extracted all available information on the method used to conceal the allocation sequence in sufficient detail to help determine whether intervention allocations could have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>Methods of blinding, including, where reported, whether these applied to each main outcome (or class of outcomes), and whether there was blinding of participants, study personnel (e.g. treating clinicians), and outcome assessors. Authors extracted sufficient information about the blinding methods, where reported, to assist in making a judgement about whether the intended blinding was effective. </p> </li> <li> <p>Whether any randomised participants had been excluded from reported analyses (for each outcome). Authors extracted reasons for attrition/exclusions, where reported. </p> </li> <li> <p>Duration of any baseline period during which seizure frequency or ADHD symptoms were assessed </p> </li> <li> <p>Duration of treatment period (including recording any drug titration periods)</p> </li> <li> <p>Description of control methods used (i.e. details of the placebo/active control/usual care used) </p> </li> <li> <p>Any evidence of selective reporting of outcomes</p> </li> </ol> </li> <li> <p><b>Participants</b> </p> <ol id="CD013136-list-0012"> <li> <p>Number of participants</p> </li> <li> <p>Age of participants</p> </li> <li> <p>Gender of participants</p> </li> <li> <p>How ADHD was diagnosed (i.e. according to which criteria)</p> </li> <li> <p>Duration of ADHD</p> </li> <li> <p>Severity of ADHD (any reported scale)</p> </li> <li> <p>How epilepsy was diagnosed (i.e. according to which criteria)</p> </li> <li> <p>Duration of epilepsy</p> </li> <li> <p>Type of epilepsy (as described in manuscript)</p> </li> <li> <p>Type of seizures (as described in manuscript)</p> </li> <li> <p>Baseline seizure frequency</p> </li> <li> <p>Comorbidity and concurrent drugs or interventions, including name and dose of ASM</p> </li> </ol> </li> <li> <p><b>Interventions</b> </p> <ol id="CD013136-list-0013"> <li> <p>Name of stimulant or non‐stimulant drug(s) used during trial</p> </li> <li> <p>Dose of stimulant or non‐stimulant drug(s) used during trial</p> </li> <li> <p>Frequency of stimulant or non‐stimulant drug(s) used during trial</p> </li> </ol> </li> <li> <p><b>Outcomes:</b> we used change from baseline data where available. If such data were not available, we either used the separate baseline data and end of follow‐up estimates described by the study authors, or calculated these ourselves. If studies did not report baseline data or end of follow‐up data, it was not possible for review authors to calculate effect estimates. </p> </li> <li> <p><b>Analysis</b> </p> <ol id="CD013136-list-0014"> <li> <p>Statistical methods used, including whether analysis was by intention‐to‐treat (ITT)</p> </li> <li> <p>What was done with missing or incomplete data and dropout participants</p> </li> <li> <p>Effect sizes (including variance, proportions, difference in proportions, risk ratios (RRs), odds ratios, difference in mean/median seizure severity scores) </p> </li> <li> <p>P values and confidence intervals quoted</p> </li> </ol> </li> </ol> </p> </section> <section id="CD013136-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CE and KY) independently assessed risk of bias for each study across the domains outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013136-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). A third review author (RFMC) resolved any disagreements that arose. We graded each potential source of bias as high, low or unclear, and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the bias domains. </p> <p>Cochrane's risk of bias domains are as follows.</p> <p> <ol id="CD013136-list-0015"> <li> <p><b>Selection bias:</b> were there adequate methods of random sequence generation and allocation concealment? Methods considered to confer a low risk of selection bias include those using random numbers tables/electronically generated random numbers for random sequence generation, and those using allocation of sequentially numbered sealed packages of medication, sealed opaque envelopes, or central/telephone randomisation for allocation concealment. </p> </li> <li> <p><b>Performance bias:</b> was knowledge of the allocated interventions by study participants and personnel (e.g. treating clinicians) adequately prevented during the study? Methods considered to confer a low risk of performance bias include using packaging and tablets that are identical for intervention and control agents. </p> </li> <li> <p><b>Detection bias:</b> was knowledge of the allocated interventions by outcome assessors prevented during the study? Studies were regarded as possessing low risks of this bias when it was specifically described that investigators/outcome assessors were blinded to treatment assignment. </p> </li> <li> <p><b>Attrition bias:</b> were incomplete outcome data adequately addressed? Studies were regarded as possessing low risks of this bias when it is clear all participants (including missing participants and missing data) were accounted for by authors, e.g. by explaining reasons for missing data, participants, and changing denominators. </p> </li> <li> <p><b>Reporting bias:</b> risk of selective reporting was judged to be low when the results of all outcomes measured were also published. </p> </li> </ol> </p> <p>We also assessed whether bias from study funding may be present, and described this under the 'Other bias' section of the risk of bias table. This is summarised below. </p> <p><b>Funding bias:</b> bias related to funding source resulting from systematic influences on how the study was conducted. This largely relates to pharmaceutical industry‐sponsored studies. These are more likely to have favourable efficacy and harm results than studies not sponsored by industry (<a href="./references#CD013136-bbs2-0061" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>). Therefore, we judged industry‐sponsored studies to have a high risk of funding bias if we deemed their methodology to have been conducted differently to standard accepted methods (i.e. following CONSORT guidelines) or differently to non‐industry‐funded studies testing the same drug. </p> </section> <section id="CD013136-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs), and calculated the risk difference (RD). Where different trials used the same instrument to measure a particular continuous outcome, we calculated mean differences (MD) with 95% CIs. Where trials used different measurement tools, we planned to calculate standardised mean differences (SMDs) with 95% CIs. If trials did not report means and standard deviations but did report other values (such as t‐tests or P values), we transformed these into standard deviations. </p> <p>The primary outcome of interest was whether stimulants or non‐stimulants alter seizure outcomes. Therefore, we defined treatment harm or effect as any increase or decrease (compared to baseline), respectively, in seizure frequency (continuous outcome), severity scores (continuous outcome), number of episodes of status epilepticus (continuous outcome), number of seizure‐related hospitalisations (continuous outcome), and proportion of people not achieving 50% or greater reduction in seizure frequency (dichotomous outcome). We defined secondary outcome treatment effects as change from baseline in ADHD symptom scores (continuous outcome), general behaviour scores (continuous outcome), cognitive effect scores (continuous outcome), and QoL scores (continuous outcome). We also compared treatments and controls for significant differences in the proportion of people experiencing adverse drug events and drug withdrawal (dichotomous outcomes). We reported 95% CIs for all comparisons except for the comparison of individual adverse effects, where we reported 99% CIs to make allowance for multiple testing. </p> </section> <section id="CD013136-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For cross‐over studies, we only used data from the first treatment phase when there was evidence of significant carryover of treatment effect into the second treatment phase. We judged there to have been a significant carryover of effect when this was stated to be the case by authors, or when there was no return to baseline seizure frequency during the second baseline/washout period. </p> </section> <section id="CD013136-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Primary analysis was on an intention‐to‐treat (ITT) basis. For this, we analysed all randomised participants in the treatment group to which they had been allocated, irrespective of the treatment that they actually received. We obtained any missing data for this by contacting trial authors. When missing data were unobtainable, we conducted analyses using the available published data (<a href="./references#CD013136-bbs2-0094" title="StorebøO , RamstadE , KroghH , NilausenT , SkoogM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>), with the assumption that data were missing at random (<a href="./references#CD013136-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). In order to assess the impact of missing data on the overall conclusions through attrition and reporting biases, we carried out sensitivity analysis that excluded data from trials judged to have high risks of bias for incomplete outcome data and selective reporting. </p> <p>In addition, we conducted best‐ and worst‐case sensitivity analyses to deal with missing dichotomous data for the outcomes of 50% reduction in seizure frequency and treatment withdrawal. </p> <p> <ol id="CD013136-list-0016"> <li> <p>Worse‐case analysis: participants randomised but excluded from analysis (e.g. for not completing follow‐up) were assumed to have failed to achieve 50% or greater reduction in seizure frequency or to have withdrawn from treatment in the intervention group, and achieved 50% or greater reduction in seizure frequency or not withdrawn from treatment in the control group. </p> </li> <li> <p>Best‐case analysis: participants randomised but excluded from analysis (e.g. for not completing follow‐up) were assumed to have achieved 50% or greater reduction in seizure frequency or to have not withdrawn from treatment in the intervention group, and failed to achieve 50% or greater reduction in seizure frequency or to have withdrawn from treatment in the control group (<a href="./references#CD013136-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </li> </ol> </p> </section> <section id="CD013136-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where possible, we planned to check statistical heterogeneity between trials for each outcome using a Chi<sup>2</sup> test for heterogeneity and the I<sup>2</sup> statistic, interpreted as follows: </p> <p> <ol id="CD013136-list-0017"> <li> <p>heterogeneity may not be important (I<sup>2</sup> values 0% to 40%); </p> </li> <li> <p>moderate heterogeneity (I<sup>2</sup> values 30% to 60%); </p> </li> <li> <p>substantial heterogeneity (I<sup>2</sup> values 50% to 90%); and </p> </li> <li> <p>considerable heterogeneity (I<sup>2</sup> values 75% to 100%) (<a href="./references#CD013136-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </li> </ol> </p> <p>Provided no significant heterogeneity was present (P &lt; 0.05 on the Chi<sup>2</sup> test, or the I<sup>2</sup> statistic &lt; 50%), we planned to conduct meta‐analysis using a fixed‐effect model. Where significant heterogeneity existed, we planned to conduct meta‐analysis using a random‐effects model and explore heterogeneity using subgroup analyses, as described in the <a href="#CD013136-sec-0036">Subgroup analysis and investigation of heterogeneity</a> section, according to the various demographic, clinical and trial characteristics (<a href="./references#CD013136-bbs2-0051" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>Due to the small number of included studies, we were unable to undertake the above.</p> </section> <section id="CD013136-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We judged the risk of selective reporting to be low when the results of all outcomes measured by trialists were also published. We requested unpublished data from authors of those papers that we judged to have a high risk of reporting bias, to help increase the size of the evidence base for analysis. </p> </section> <section id="CD013136-sec-0035"> <h4 class="title">Data synthesis</h4> <p>For each study, we reported the overall effect of the stimulant or non‐stimulant drugs used on the primary and secondary outcomes described. We also planned to use these results to perform a meta‐analysis, where possible. Where heterogeneity precluded the provision of precise estimates, we planned to provide a descriptive analysis of the overall trends in evidence, and use subgroup analyses to help identify factors that may help explain the heterogeneity (see <a href="#CD013136-sec-0036">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD013136-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, subgroup analyses on the following groups were planned to help identify whether these groups were affected by stimulant/non‐stimulant drugs differently, or to help investigate heterogeneity. </p> <p> <ol id="CD013136-list-0018"> <li> <p>Children versus adults: the cutoff age for childhood is 16 or 18 years in different countries, where 16 to 18 years is described as adolescence. We planned to group children and adolescents together. </p> </li> <li> <p>Males versus females</p> </li> <li> <p>Comorbidity: participants with ADHD and epilepsy with additional comorbid disorders versus those without additional comorbid disorders; </p> </li> <li> <p>Type of epilepsy: we planned to compare: generalised epilepsy, focal epilepsy, generalised and focal epilepsy, and unknown if generalised or focal epilepsy. </p> </li> <li> <p>Type of ADHD: participants with predominantly inattentive subtype versus participants with predominantly combined subtype (<a href="./references#CD013136-bbs2-0094" title="StorebøO , RamstadE , KroghH , NilausenT , SkoogM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>) </p> </li> <li> <p>Study location: we planned to group studies together by continent and compare the different continents. </p> </li> <li> <p>Intervention: we planned to group studies and compare them by the particular stimulant or non‐stimulant drug used, when more than one study had used the same drug. </p> </li> <li> <p>Studies at low risk of bias versus studies at unclear or high risk of bias: we planned to group studies with low risk of bias (all domains) together and compare these against studies with unclear or high risk of bias. </p> </li> <li> <p>Industry and non‐industry studies: we planned to group together studies funded by the pharmaceutical industry and compare them against studies without industry funding. </p> </li> </ol> </p> <p>Due to the small number of included studies, we were unable to undertake the above.</p> </section> <section id="CD013136-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct best‐ and worst‐case sensitivity analyses as described above to deal with missing dichotomous data (see <a href="#CD013136-sec-0032">Dealing with missing data</a>). </p> <p>Due to the small number of included studies (one study for each drug), we were unable to perform a sensitivity analysis in which we would have excluded data from studies with high or unclear risk of bias from the analysis, in order to assess the impact of these biases on the overall conclusions. </p> </section> <section id="CD013136-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We interpreted findings using the GRADE approach (<a href="./references#CD013136-bbs2-0090" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6/.">Schunemann 2019</a>). We used <a href="./references#CD013136-bbs2-0047" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEPro GDT</a> software, into which we imported data from Review Manager 5 (<a href="./references#CD013136-bbs2-0077" title="Review Manager 5 (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), to create summary of findings tables for each comparison included in the review for the following outcomes. </p> <p> <ol id="CD013136-list-0019"> <li> <p>Seizure frequency</p> </li> <li> <p>Proportion of people experiencing drug withdrawal</p> </li> <li> <p>Seizure severity</p> </li> <li> <p>Proportion of people achieving 50% or greater reduction in seizure frequency</p> </li> <li> <p>ADHD symptoms</p> </li> <li> <p>Proportion of people experiencing adverse drug events</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013136-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013136-sec-0039"></div> <section id="CD013136-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013136-sec-0109" title="">Characteristics of included studies</a>, <a href="./references#CD013136-sec-0110" title="">Characteristics of excluded studies</a> and <a href="./references#CD013136-sec-0111" title="">Characteristics of ongoing studies</a> for the details of the studies considered for this review. </p> <section id="CD013136-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search identified 199 records. After removal of duplicates, 164 records remained. Review authors screened the titles and abstracts of these records and selected 20 to be assessed in full‐text. On full‐text review, an additional 14 records were excluded (see <a href="./references#CD013136-sec-0110" title="">Characteristics of excluded studies</a>). We identified one study which we classified as ongoing. We contacted the authors, who responded informing us that this study was completed and was currently being prepared for publication (see <a href="./references#CD013136-sec-0111" title="">Characteristics of ongoing studies</a>). We included two studies, described in five records, in our review. The study selection process is summarised in <a href="#CD013136-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013136-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013136-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013136-sec-0042"> <h4 class="title">Included studies</h4> <p>We included two studies with a total of 94 participants (<a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>; <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>). </p> <section id="CD013136-sec-0043"> <h5 class="title"><i>Study design</i> </h5> <p>Both trials were RCTs, randomising at the participant level. </p> <p>The aim of <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>  was to pilot a trial of osmotic‐release oral system methylphenidate, known as OROS methylphenidate (OROS‐MPH), to treat people with ADHD and epilepsy. Thirty‐three people took part in the double‐blind placebo‐controlled cross‐over trial.   </p> <p>Participants were randomised to either the active treatment (OROS‐MPH) or placebo arm of the study, and crossed over to the opposite arm after a one‐week washout period. Given the sustained release of OROS‐MPH, the study employed an adaptive phase‐I dosing escalation strategy to find the maximum acceptable dose and to explore safety problems in a small number of participants. Three groups of participants were assessed sequentially: in the first group, the maximum dose was 18 mg per day, the second was 36 mg and the third 54 mg. Recruitment into the 36 mg group could not begin until at least three participants had completed the cross‐over trial for the 18 mg dose without a significant worsening of epilepsy or a serious adverse event, with this process repeated for the 54 mg group. It is important to note that the maximum dose was the lesser of 54 mg or 2 mg/kg/day, therefore even if a higher dose group had begun recruiting (e.g. group II), the participant could still be assigned to the lower group (e.g. group I) to ensure the maximum dose remained below 2 mg/kg/day. If at any of the three dose levels two participants had significant worsening of epilepsy (see <a href="./references#CD013136-sec-0109" title="">Characteristics of included studies</a> for a definition) during the active arm, the dose level immediately below would be fixed as the maximum dose for the rest of the study (this did not occur and so all three dose levels were tested). </p> <p>Participants spent a week on the maximum dose before endpoint measures for that arm were taken, and the participant crossed over to the opposite arm. Therefore, for group I, the treatment period lasted for three weeks (one week of 18 mg OROS‐MPH, one week of washout, one week of placebo), for group II, five weeks (one week of 18 mg OROS‐MPH, one week of 36 mg OROS‐MPH, one week washout, two weeks of placebo) and for group III, seven weeks, (one week of 18 mg OROS‐MPH, one week of 36 mg OROS‐MPH, one week of 54 mg OROS‐MPH, one week washout, three weeks placebo). In all three groups, on the first day of the active arm, participants were given 5 mg or immediate‐release (IR) in the morning and at noontime. If the participant tolerated this, they moved on to completing the remaining six days on 18 mg of OROS‐MPH. The baseline period was not reported, although the authors did take a seizure history over the previous two years. </p> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> employed a single‐blind parallel‐group design, whereby participants were randomised to receive either omega‐3 with risperidone and previous ASM, or risperidone with previous ASM only. The treatment period lasted for three months, with outcome measures taken monthly. The duration of the baseline period was not reported. </p> </section> <section id="CD013136-sec-0044"> <h5 class="title"><i>Setting</i> </h5> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> was conducted in the USA and <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> was conducted in Iran. </p> <p>In <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>, participants were patients in the clinics of neurologists at Children's Hospital Boston. In <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, participants were patients of the Pediatric Neurology Clinic of Shahid Sadoughi Hospital, Yazd, Iran. </p> </section> <section id="CD013136-sec-0045"> <h5 class="title"><i>Participants</i> </h5> <p>In both included studies, participants had a dual‐diagnosis of ADHD and epilepsy; 33 in <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> and 61 in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> (although data were reported for only 56 (five participants who were randomised subsequently discontinued medication after three to four weeks). We contacted the authors of <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> to request the relevant outcome data from these five participants, however, the authors did not respond to our request.  Both studies diagnosed epilepsy according to the International League Against Epilepsy (ILAE) definition; in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, the diagnosis was refractory epilepsy specifically (<a href="./references#CD013136-bbs2-0054" title="Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30(4):389-99. [PMID: 2502382]">ILAE 1989</a>; <a href="./references#CD013136-bbs2-0040" title="FisherRS , AcevedoC , ArzimanoglouA , BogaczA , CrossJH , ElgerCE , et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia2014;55(4):475-82. [PMID: 24730690]">Fisher 2014b</a>). In both studies, ADHD was diagnosed according to <a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a> criteria (<a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a>); in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, participants were additionally required to have a score of at least 20 on an ADHD diagnostic rating scale, conducted via parent interview (<a href="./references#CD013136-bbs2-0097" title="UrionDK . Attention-Deficit/Hyperactivity Disorder. In: KliegmanR , StantonB , BehrmanRE , St Geme IIIJW , SchorNF , NelsonWE , editors(s). Nelson Textbook of Pediatrics. 20th edition. Vol. 1. Philadelphia (PA): Elsevier, 2016:200-4. [ISBN: 9781455775668]">Urion 2016</a>). Please see <a href="./references#CD013136-sec-0109" title="">Characteristics of included studies</a> for additional inclusion/exclusion criteria. The mean age of participants was 9.24 years (range 7 to 11 years) in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> and 10.5 years (range 6 to 18 years) in <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>. Both studies recruited a majority of male participants, 57.6% in <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> and 58.9% in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>.  In <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>, participants were taking ASM and had a last seizure one to 60 months prior to starting study medication. </p> </section> <section id="CD013136-sec-0046"> <h5 class="title"><i>Interventions</i> </h5> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> used a stimulant drug, whereas <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> used a non‐stimulant drug. </p> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> investigated the safety and efficacy of OROS‐MPH, a sustained‐release stimulant drug. As described in 'Study Design<i>'</i>, different dose levels of the drug were tested to establish a maximum acceptable dose; 18 mg, 36 mg and 54 mg (or no more than 2 mg/kg/per day), with the participant remaining on the maximum dose for one week. The drug was administered orally on a daily basis in the morning. Before testing OROS‐MPH, participants were initially given 5 mg of IR‐MPH on the first day of the active arm at morning and at noontime to see if they tolerated this dose. Participants in the control arm received a placebo. </p> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> explored the safety and efficacy of fish oil (omega‐3), from 21st Century Co., USA. Each capsule contained 1000 mg of fish oil, 180 mg of eicosapentaenoic acid and 120 mg of docosahexaenoic acid. Each day, participants in the active arm received one capsule, along with a 1 mg of risperidone (Abdi Co., Iran) divided into two doses, and their usual regimen of ASM. In the control arm, participants received only the risperidone and previous ASM. Drugs were delivered by the mothers of the participants and continued for three months.   </p> </section> <section id="CD013136-sec-0047"> <h5 class="title"><i>Outcomes</i> </h5> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> assessed outcome measures after the participant had remained on the maximum dose of OROS‐MPH or placebo for one week, except where noted. <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, assessed outcomes measures on a monthly basis for three consecutive months. </p> <section id="CD013136-sec-0048"> <h6 class="title"><i>Primary outcomes</i> </h6> <section id="CD013136-sec-0049"> <p><b><i>Seizure frequency </i> </b></p> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> provided data on the total number of seizures that occurred in the OROS‐MPH and placebo arms, as well as by dose in the OROS‐MPH group. <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> measured the mean monthly seizure frequency across the three‐month research period, and compared this between the omega‐3 and placebo arms. Neither study included a comparison to baseline when exploring seizure frequency. </p> </section> <section id="CD013136-sec-0050"> <p><b><i>Proportion of people withdrawing from treatment</i> </b></p> <p>Both <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> and <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> provided data on the proportion of people withdrawing from treatment. <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> included this as an outcome within their study and compared this variable between the OROS‐MPH and placebo arms. <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> reported the number of randomised participants who discontinued medication after three to four weeks, but did not include this as an outcome or compare this between the omega‐3 and placebo arms in their analyses. </p> </section> </section> <section id="CD013136-sec-0051"> <h6 class="title"><i>Secondary outcomes</i> </h6> <section id="CD013136-sec-0052"> <p><b><i>Seizure severity </i> </b></p> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> included a measure of seizure severity as part of their assessment of whether participants experienced 'significant worsening of epilepsy' during treatment. This was defined as: 1) a doubling of the highest 14‐day or two‐day seizure rate observed during the 12 months preceding the trial; 2) the occurrence of a generalised tonic‐clonic seizure if the participant had not experienced one in the previous two years; or, 3) an intensification of seizure severity or frequency determined to be clinically meaningful.  </p> </section> <section id="CD013136-sec-0053"> <p><b><i>Proportion of people achieving 50% or greater reduction in seizure frequency</i> </b></p> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> measured the proportion of participants who achieved 50% or greater reduction in seizure frequency (relative to baseline) in the omega‐3 and control groups. </p> </section> <section id="CD013136-sec-0054"> <p><b><i>ADHD symptoms</i> </b></p> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> measured ADHD symptoms using the ADHD Rating Scale IV Home Version (ADHD‐RS, <a href="./references#CD013136-bbs2-0035" title="DuPaulGJ , PowerTJ , AnastopoulosAD , ReidR . ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation. New York (NY): Guilford Press, 1998. [ISBN: ‎ 978-1572304239]">DuPaul 1998</a>), which consists of 18 items, with each item corresponding to one of the <a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a> ADHD criteria. The Principal Investigator (PI) read out each item to the participant's guardian and then rated the participant's symptom severity over the preceding week. In addition, this study used the 'Severity' and 'Improvement' subscales of the Clinical Global Impressions for ADHD scale (CGI‐ADHD, <a href="./references#CD013136-bbs2-0049" title="GuyW . Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:217-222. [DHEW PUBLICATION NO. (ADM): 76-338] [URL: archive.org/details/ecdeuassessmentm1933guyw]">Guy 1976</a>) to assess symptom severity and symptom improvement after the intervention, respectively. Both subscales are single‐item ratings, given by a clinician. The 'Severity' subscale reflects a clinician's assessment of the global severity of the child's ADHD symptoms in relation to total experience with them, and uses a 7‐point scale: 1 = normal, not at all, and 7 = among the most extremely ill patients. The 'Improvement' subscales measure the global change in the child's ADHD symptoms; in this study, the clinician provided the rating at the final visit of each arm. A score of either 1 = very much improved or 2 = much improved were collectively defined as 'response'. </p> </section> <section id="CD013136-sec-0055"> <p><b><i>Proportion of people experiencing adverse drug events</i> </b></p> <p>Both trials measured the proportion of participants experiencing adverse drug effects. In <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>, the PI rated adverse events from mild to life‐threatening and also measured the severity of these events using the Barkley Side Effects Checklist‐Modified (BSCEM, <a href="./references#CD013136-bbs2-0019" title="BarkleyRA , McMurrayMB , EdelbrockCS , RobbinsK . Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics1990;86(2):184-92. [PMID: 2196520]">Barkley 1990</a>). This assesses 24 side effects linked to stimulant medication use. The authors defined a 'dose limiting adverse‐event' (in which the participant would discontinue the arm of the cross‐over they were currently participating in) if one of the BSCEM items was elevated above baseline at a moderate or higher level. </p> </section> </section> </section> <section id="CD013136-sec-0056"> <h5 class="title"><i>Funding sources </i> </h5> <p>Both studies reported information on their source of funding; <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> was funded by an NIMH Grant K23 MH066835 and <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> was funded by a grant from the Deputy for Research of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. </p> </section> </section> <section id="CD013136-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies. In seven studies, participants did not have a dual‐diagnosis of ADHD and epilepsy, six had an ineligible study design (they were not randomised controlled trials) and one was a literature review. </p> </section> </section> <section id="CD013136-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>See also <a href="#CD013136-fig-0002">Figure 2</a> and <a href="#CD013136-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013136-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013136-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD013136-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013136-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013136-sec-0059"> <h4 class="title">Allocation</h4> <p>In <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>, randomisation lists for each of the three dose groups were prepared by a statistician and maintained by the study research pharmacist. However, there was no report of how these lists were randomised, nor the process for allocation concealment. We therefore considered both sequence generation and allocation concealment to be at unclear risk in <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>. By contrast, in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, an investigator with no clinical involvement in the trial randomly allocated participants into either the intervention or control group using computer‐generated equal simple randomisation by random numbers. Numbered, sealed opaque envelopes containing the group number for each child were used for concealment, opened by the paediatric neurologist in the research study immediately before study enrolment. We therefore rated both sequence generation and allocation concealment as low risk in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>. </p> </section> <section id="CD013136-sec-0060"> <h4 class="title">Blinding</h4> <p>In <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a>, the participants, study personnel and the outcome assessor were all blind to medication status. We considered <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> to be at low risk for blinding of participants and study personnel, as well as blinding of outcome assessors. In <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, we considered blinding of participants and study personnel to be at high risk as, given the design of the study (i.e. no placebo), the mothers in the intervention arm of the trial were aware they were administering omega‐3 to their child. All outcome assessors were, however, kept blinded to the allocation, so we rated the 'Blinding of outcome assessors' domain as low risk. </p> </section> <section id="CD013136-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We considered <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> to be at low risk of incomplete outcome data; all 33 randomised participants were included in the analyses. By contrast, we rated <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> as high risk in this domain; five participants who had been randomised were excluded as a result of discontinuing medication after three to four weeks. </p> </section> <section id="CD013136-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We considered both <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> and <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> to be at low risk for selective outcome reporting, as all analyses and planned outcomes described in the methods section were subsequently reported in the results. </p> </section> <section id="CD013136-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Several of the <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> study authors received funding from McNeil Consumer Health, who provided the active OROS methylphenidate and matching placebo for the study. Therefore, we considered this trial to be at high risk of funding bias. We considered <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> to be at low risk of funding bias, as university departmental funding was declared (a grant from the Deputy for Research of Shahid Sadoughi University of Medical Sciences, Yazd, Iran). </p> </section> </section> <section id="CD013136-sec-0064"> <h3 class="title" id="CD013136-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD013136-tbl-0001"><b>Summary of findings 1</b> Osmotic‐release oral system methylphenidate compared to placebo for people with ADHD and epilepsy</a>; <a href="./full#CD013136-tbl-0002"><b>Summary of findings 2</b> Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy</a> </p> <p>The diversity of stimulant/non‐stimulant drugs measured, study design and reported outcomes meant that we were unable to pool data from the two studies included in our review. We therefore did not conduct analyses of statistical heterogeneity or any of the subgroup analyses (see items 1 to 9 in <a href="#CD013136-sec-0036">Subgroup analysis and investigation of heterogeneity</a>). We present data on key outcomes for each of the two key comparisons in this review, and describe our confidence in the results based on GRADE criteria (<a href="./references#CD013136-bbs2-0090" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6/.">Schunemann 2019</a>). </p> <section id="CD013136-sec-0065"> <h4 class="title">OROS‐MPH versus control</h4> <p>See <a href="./full#CD013136-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013136-sec-0066"> <h5 class="title"><i>Primary outcomes</i> </h5> <section id="CD013136-sec-0067"> <h6 class="title"><i>1. Seizure frequency (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> found that eight seizures occurred on seven out of a total 1058 days of placebo or OROS‐MPH. Three seizures occurred during 565 placebo days (rate = 0.53 seizures/100 days). One seizure occurred during 194 days of either 10 mg or 18 mg OROS‐MPH (0.52 seizures/100 days). Two seizures occurred during 170 days of 36 mg OROS‐MPH (1.12 seizures/100 days). Two seizures occurred during 87 days of 54 mg OROS‐MPH (2.30 seizures/100 days). </p> <p>Given that, if the participant experienced a seizure in either the OROS‐MPH or control arm, they discontinued that arm, the authors used logistic regression models to explore the odds of a seizure on each day of exposure to OROS‐MPH or placebo. They found that significant predictors of seizure risk were: the number of days of exposure to placebo or OROS‐MPH (P &lt; 0.005), the drug dose (P &lt; 0.005), and the interaction between them (P = 0.002 when drug dose examined as mg/kg/day and P &lt; 0.001 when examined as absolute dose). The authors also used Cox proportional hazard models to explore time to seizure and hazard at each dose. They found a higher mg/kg/day dose predicted a greater hazard of a seizure (P &lt; 0.001). Days of exposure was not significant in this model, but the interaction between days of exposure and dose was (P &lt; 0.05). We had low confidence in these findings. We downgraded certainty by one level due to risk of bias: this study was rated 'unclear' for random sequence generation and allocation concealment, as well as high for other bias ‐ several authors received funding from McNeil Consumer Health, the provider of active OROS methylphenidate and matching placebo for this study. We downgraded certainty by another level due to indirectness: this did not compare the mean seizure frequency (change from baseline) as an outcome between the OROS‐MPH and the placebo arms. </p> </section> <section id="CD013136-sec-0068"> <h6 class="title"><i>2. Proportion of people withdrawing from treatment</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> explored the proportion of people withdrawing from treatment. If a dose‐limiting adverse event occurred (if one of the BSCEM items was elevated above baseline at a moderate or higher level), the participant withdrew from the OROS‐MPH/placebo arm of the cross‐over they were participating in. Fourteen out of 33 (42.4%) participants discontinued OROS‐MPH and 5/33 (15.2%) discontinued the placebo. This difference was statistically significant (P = 0.007). The risk ratio was 2.80 (95% CI 1.14 to 6.89) (<a href="./references#CD013136-fig-0004" title="">Analysis 1.1</a>), and the risk difference was 0.27 (95% CI 0.06 to 0.48). We had moderate certainty in these findings, and downgraded certainty by one level due to risk of bias. </p> </section> </section> <section id="CD013136-sec-0069"> <h5 class="title"><i>Secondary outcomes</i> </h5> <section id="CD013136-sec-0070"> <h6 class="title"><i>1. Seizure severity (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> included a measure of seizure severity as part of their assessment of whether participants had 'worsening of epilepsy' during the study. They defined significant worsening of epilepsy as: 1) a doubling of the highest 14‐day or two‐day seizure rate observed during the 12 months preceding the trial; 2) the occurrence of a generalised tonic‐clonic seizure if the participant had not experienced one in the previous two years; or, 3) an intensification of seizure severity or frequency determined to be clinically meaningful. No participants in either the OROS‐MPH or placebo arms experienced significant worsening of epilepsy. We had low certainty in these findings, and downgraded certainty by one level due to risk of bias and another level due to indirectness because the study did not explore seizure severity (change from baseline) as a continuous outcome, instead, seizure severity formed part of the dichotomous outcome 'worsening of epilepsy'. </p> </section> <section id="CD013136-sec-0071"> <h6 class="title"><i>2. Number of episodes of status epilepticus (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> did not measure the number of episodes of status epilepticus. </p> </section> <section id="CD013136-sec-0072"> <h6 class="title"><i>3. Number of seizure‐related hospitalisations (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> explored the proportion of people who experienced serious adverse events, but did not provide a further breakdown of whether this included seizure‐related hospitalisations. </p> </section> <section id="CD013136-sec-0073"> <h6 class="title"><i>4. Proportion of people achieving 50% or greater reduction in seizure frequency (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> did not measure the proportion of people achieving a 50% or greater reduction in seizure frequency. </p> </section> <section id="CD013136-sec-0074"> <h6 class="title"><i>5. ADHD symptoms</i> </h6> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> found that a greater proportion of participants received 'much improved' or 'very much improved' scores for ADHD symptoms on the CGI‐ADHD‐I in the OROS‐MPH arm relative to the placebo arm (descriptive comparison only). Total ADHD‐RS scores dropped across both the OROS‐MPH and placebo arms (week of treatment, P &lt; 0.0001), but dropped more rapidly in the OROS‐MPH arm (significant interaction between week of treatment and OROS‐MPH/placebo arm, P &lt; 0.0001). We had low confidence in these findings; we downgraded certainty by one level due to risk of bias and by one level due to indirectness: this study did not present the exact proportion of participants showing improvement in ADHD symptoms, or exact numbers for the change in total ADHD‐RS score. Data were provided in figures, which prevented accurate estimates and therefore precluded risk ratio and mean difference calculations in this review. We contacted the study authors and asked to obtain these data, but the authors did not respond. </p> </section> <section id="CD013136-sec-0075"> <h6 class="title"><i>6. Proportion of people experiencing adverse events during follow‐up</i> </h6> <p>No participants in either the OROS‐MPH or control arms experienced serious adverse events. We had moderate certainty in these findings, and downgraded certainty by one level due to risk of bias. </p> <p>This study measured milder, individual adverse affects across the OROS‐MPH and placebo arms. Four participants in the OROS‐MPH arm experienced worsened emotional lability (4/33, 12.1%) compared to two in the control arm (2/33, 6.1%). The risk ratio was 2.0 (99% CI 0.24 to 16.98) (<a href="./references#CD013136-fig-0005" title="">Analysis 1.2</a>) and the risk difference was 0.06 (99%% CI 0.06 to 0.24). Four participants experienced a seizure in the OROS‐MPH arm (4/33, 12.1%) compared to three in the control arm (3/33, 9.1%). The authors found this difference was not statistically significant. The risk ratio was 1.33 (99% CI 0.21 to 8.58) (<a href="./references#CD013136-fig-0005" title="">Analysis 1.2</a>) and the risk difference was 0.03 (99% CI ‐0.16 to 0.23). </p> </section> </section> </section> <section id="CD013136-sec-0076"> <h4 class="title">Omega‐3 versus control</h4> <p>See <a href="./full#CD013136-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013136-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD013136-sec-0078"> <h6 class="title"><i>1. Seizure frequency</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> compared mean monthly seizure frequency between the omega‐3 and control groups over a three‐month treatment period. The omega‐3 group had a mean monthly seizure frequency of 10.4 (SD 3.92), which was significantly lower than that of the control group (17.0, SD 4.98; P = 0.003). The mean difference was ‐6.6 in the omega‐3 group relative to control (95% CI ‐8.96 to ‐4.24) (<a href="./references#CD013136-fig-0006" title="">Analysis 2.1</a>. We had low confidence in these findings. We downgraded certainty by one level due to high risk of bias in the 'blinding of participants and study personnel' domain and the 'incomplete outcome data' domains. We also downgraded by one level due to indirectness; this study did not compare seizure frequency in omega‐3 and control groups based on change from baseline. Importantly, a comparison of baseline seizure frequency between omega‐3 and control revealed a descriptive trend towards a lower seizure frequency in the omega‐3 group (mean 15.8, SD 8.49) relative to control (mean 16.7, SD 6.68) which approached significance (P = 0.09). </p> </section> <section id="CD013136-sec-0079"> <h6 class="title"><i>2. Proportion of individuals withdrawing from treatment</i> </h6> <p>After three to four weeks of treatment, two participants in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> discontinued omega‐3 and three participants in the control group discontinued risperidone. The risk ratio was 0.65 (95% CI 0.12 to 3.59) (<a href="./references#CD013136-fig-0007" title="">Analysis 2.2</a>) and the risk difference was ‐0.04 (95% CI ‐0.17 to 0.1). We had low confidence in these findings. We downgraded certainty by one level due to high risk of bias in the 'blinding of participants and study personnel' domain and the 'incomplete outcome data' domains. We also downgraded by one level due to imprecision; only a small number of participants withdrew from treatment and confidence intervals for the effect on withdrawal are consistent with both a decrease and increase in risk in the omega‐3 group. </p> </section> </section> <section id="CD013136-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD013136-sec-0081"> <h6 class="title"><i>1. Seizure severity (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> did not measure seizure severity. </p> </section> <section id="CD013136-sec-0082"> <h6 class="title"><i>2. Number of episodes of status epilepticus (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> did not measure the number of episodes of status epilepticus. </p> </section> <section id="CD013136-sec-0083"> <h6 class="title"><i>3. Number of seizure‐related hospitalisations (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> did not measure the number of seizure‐related hospitalisations. </p> </section> <section id="CD013136-sec-0084"> <h6 class="title"><i>4. Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline)</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> compared the proportion of people achieving 50% or greater reduction in seizure frequency, relative to baseline, in the omega‐3 and control groups. They found that a significantly greater proportion of individuals in the omega‐3 arm experienced ≥ 50% reduction (31%) than did individuals in the control group (11.1%). However, our calculations of the risk ratio (2.79, 95% CI 0.84 to 9.24; <a href="./references#CD013136-fig-0008" title="">Analysis 2.3</a>) and risk difference (0.20, 95% CI ‐0.01 to 0.41) indicated uncertainty about whether omega‐3 increased or decreased the likelihood of achieving a 50% reduction in seizure frequency. We had low certainty in these findings, downgrading by one level due to high risk of bias in the 'blinding of participants and study personnel' domain and the 'incomplete outcome data' domains and by one level due to imprecision, as a result of the mixed results from the best‐ and worst‐case scenario sensitivity analyses (see below). </p> <p>Given that five participants randomised in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> were excluded from the analysis due to discontinuing medication, we conducted best‐ and worst‐case scenario sensitivity analyses for this outcome. In the best‐case scenario, it was assumed that participants withdrawing from the omega‐3 group did achieve a 50% or greater reduction in seizure frequency and those in the control group did not. The risk ratio was 3.55 (95% CI 1.10 to 11.48; <a href="./references#CD013136-fig-0009" title="">Analysis 2.4</a>) and the risk difference was 0.25 (95% CI 0.06 to 0.45), indicating an increase in the likelihood of achieving a 50% or greater reduction in seizure frequency. In the worst‐case scenario, it was assumed that participants withdrawing from the omega‐3 group did not achieve a 50% or greater reduction in seizure frequency and that those in the control group did. The risk ratio was 1.45 (95% CI 0.59 to 3.58; <a href="./references#CD013136-fig-0010" title="">Analysis 2.5</a>) and the risk difference was 0.09 (95% CI ‐0.12 to 0.30). </p> </section> <section id="CD013136-sec-0085"> <h6 class="title"><i>5. Proportion of people experiencing adverse events during follow‐up</i> </h6> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> explored the proportion of participants in the omega‐3 and control groups who experienced an adverse event over the three‐month treatment period. Six participants in the intervention group (20.7%) experienced an adverse event: two experienced sleepiness, two diarrhoea and two nausea and vomiting. In the control group, four participants (14.8%) experienced an adverse event: two experienced sleepiness, one anorexia and one constipation. The trial authors found the proportion of participants experiencing an adverse event did not differ between the omega‐3 and control group. The risk ratio for an adverse event in the omega‐3 group was 1.40 (95% CI 0.44 to 4.42) (<a href="./references#CD013136-fig-0011" title="">Analysis 2.6</a>), and the risk difference was 0.06 (95% CI ‐0.14 to 0.26). We had low confidence in these findings and downgraded by one level due to high risk of bias in the 'blinding of participants and study personnel' domain and the 'incomplete outcome data' domain. We also downgraded by one level due to imprecision: only a small number of adverse events occurred, and confidence intervals for the effect of omega‐3 are consistent with both appreciable harm and benefit. </p> <p><a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> also reported the proportion of participants with individual adverse effects across the omega‐3 and control arms (<a href="./references#CD013136-fig-0012" title="">Analysis 2.7</a>). Two participants experienced sleepiness in the omega‐3 arm (2/29, 6.9%), as did two participants in the control arm (2/27, 7.4%). The risk ratio was 0.93 (99% CI 0.08 to 11.14) and the risk difference was ‐0.01 (99% CI 0.18 to 0.17). Two participants suffered from diarrhoea in the omega‐3 arm (2/27, 7.4%), compared to none in the control arm. The risk ratio was 4.67 (99% CI 0.09 to 238.19) and the risk difference was 0.07 (99% CI ‐0.08 to 0.21). Two participants experienced nausea and vomiting in the omega‐3 arm (2/27, 7.4%) compared to none in the control arm. The risk ratio was 4.67 (99% CI 0.09 to 238.19) and the risk difference was 0.07 (99% CI ‐0.08 to 0.21). One participant experienced anorexia and one experienced constipation in the control arm; none of the participants in the omega‐3 arm experienced these conditions. For both anorexia and constipation, the risk ratios were 0.31 (99% CI 0.00 to 19.76) and the risk differences were ‐0.04 (99% CI 0.16 to 0.09). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013136-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013136-sec-0086"></div> <section id="CD013136-sec-0087"> <h3 class="title" id="CD013136-sec-0087">Summary of main results</h3> <p>This is the first study to systematically review the efficacy and tolerability of stimulant and non‐stimulant drugs in people with a dual‐diagnosis of ADHD and epilepsy, within clinical trials. Our review found only two RCTs which matched our inclusion criteria. Both studies focused on children with a dual‐diagnosis of ADHD and epilepsy, but explored different drugs; <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> explored the stimulant drug OROS‐MPH, whereas <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> explored the non‐stimulant omega‐3 fish oil. The two studies also employed different designs; <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> employed a parallel‐group design to compare omega‐3 taken in tandem with risperidone and the participant's usual regiment of ASM with risperidone and ASM only, whereas <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> employed a cross‐over design to compare different doses of OROS‐MPH with a placebo. </p> <p><a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> found that increasing the dose of OROS‐MPH was associated with an increase in the daily risk of a seizure, although there is low certainty surrounding these findings. This reduced certainty is due to study biases, including funding bias and lack of information about method of randomisation and allocation concealment, and indirect outcomes which did not compare a change in mean seizure frequency between OROS‐MPH and placebo arms. This study also provided evidence suggesting OROS‐MPH increases the risk of adverse events and withdrawal from treatment relative to placebo. There was moderate certainty associated with these findings. Finally, <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> provided evidence suggesting OROS‐MPH improved ADHD symptoms relative to placebo, although there is low certainty associated with these findings, due to study biases and a lack of reporting of the exact change in ADHD symptom scores and the proportions showing improvement. </p> <p>Whilst <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> provided some evidence to suggest omega‐3 was associated with improved seizure outcomes (by both a reduction in mean monthly seizure frequency and an increase in the likelihood of achieving 50% or greater reduction in seizure frequency), there was low certainty associated with these findings due to study biases, which concerned the participants' mothers who were administering the drug being unblinded to medication status. There was also indirectness due to a failure to include a change from baseline when exploring seizure outcomes and imprecision as a result of confidence intervals which crossed the threshold for an increase and decrease in the likelihood of seizure reduction. This study did not provide data on seizure outcomes for five participants who were randomised but who discontinued medication; best‐case scenario sensitivity analysis indicated that omega‐3 may increase the likelihood of a 50% or greater seizure frequency reduction, with worst‐case scenario analysis proving inconclusive. <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> also explored treatment withdrawal and adverse events associated with omega‐3; again, findings were inconclusive about whether this drug increases or decreases the risk, due to study biases, a small number of adverse events and withdrawals occurring, and wide confidence intervals indicating both an appreciable treatment benefit or harm. </p> </section> <section id="CD013136-sec-0088"> <h3 class="title" id="CD013136-sec-0088">Overall completeness and applicability of evidence</h3> <p>Participants in our study had a dual‐diagnosis of ADHD and epilepsy. In both studies, epilepsy diagnoses were made according to ILAE criteria <a href="./references#CD013136-bbs2-0040" title="FisherRS , AcevedoC , ArzimanoglouA , BogaczA , CrossJH , ElgerCE , et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia2014;55(4):475-82. [PMID: 24730690]">Fisher 2014b</a> and ADHD diagnoses made according to <a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a> criteria <a href="./references#CD013136-bbs2-0032" title="American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994. [ISBN: 0-89042-061-0]">DSM‐IV</a>. However, a number of participant characteristics limit the generalisability of our findings. Firstly, our study did not include any adult participants, meaning that our findings can only be generalised to children with ADHD and epilepsy. Secondly, participants in both studies were recruited from clinic settings, so findings cannot be generalised to community settings. </p> <p>As discussed previously, our review only explored two drugs (one stimulant and one non‐stimulant), so we were unable to undertake a meta‐analysis of the data. </p> <p>The included studies did not explore several of the outcomes of interest in our review: the number of episodes of status epilepticus, the number of seizure‐related hospitalisations and effects of stimulant/non‐stimulant drugs on cognition, general behaviour and quality of life. Among those outcomes for which we had data, these often did not match the definitions set out in our protocol (<a href="./references#CD013136-bbs2-0101" title="WalterV , MbizvoGK , ChinRF . Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy. Cochrane Database of Systematic Reviews2018, Issue 9. Art. No: CD013136. [DOI: 10.1002/14651858.CD013136]">Walter 2018</a>); for example, in exploring seizure frequency, <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> did not include change from baseline scores when comparing omega‐3 and control groups. </p> <p>For a study to be included in our review, the authors must have described it as a randomised controlled trial or have described a process of random allocation into intervention groups. Whilst this improves the quality of the evidence on the efficacy and safety of stimulant and non‐stimulant drugs for people with ADHD and epilepsy, some studies will have been ineligible. For example, we did not include the studies by <a href="./references#CD013136-bbs2-0006" title="FeldmanH , CrumrineP , HandenBL , AlvinR , TeodoriJ . Methylphenidate in children with seizures and attention-deficit disorder. American Journal of Diseases of Children1989;143(9):1081-6. [PMID: 2672786]">Feldman 1989</a>, <a href="./references#CD013136-bbs2-0009" title="Gross-TsurV , ManorO , van derMeereJ , JosephA , ShalevRS . Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? [Republished from Journal of Pediatrics; 1997 Jan;130(1):40-4; PMID: 9003849]. Journal of Pediatrics1997;130(4):670-4. [PMID: 9432523]">Gross‐Tsur 1997</a> and <a href="./references#CD013136-bbs2-0048" title="GucuyenerK , ErdemogluAK , SenolS , SerdarogluA , SoysalS , KockarAI . Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. Journal of Child Neurology2003;18(2):109-12. [PMID: 12693777]">Gucuyener 2003</a> (the <a href="./references#CD013136-bbs2-0048" title="GucuyenerK , ErdemogluAK , SenolS , SerdarogluA , SoysalS , KockarAI . Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. Journal of Child Neurology2003;18(2):109-12. [PMID: 12693777]">Gucuyener 2003</a> study was not returned in our search results, but we considered it when searching through the reference list of a relevant review), all of which explored the efficacy and safety of MPH in children with ADHD and epilepsy, but which did not describe a process of random allocation into intervention groups. Our approach will also not have captured observational studies and case studies in this area. </p> </section> <section id="CD013136-sec-0089"> <h3 class="title" id="CD013136-sec-0089">Quality of the evidence</h3> <p>We used GRADE to assess the certainty of evidence for each outcome.</p> <p>For the comparison of OROS‐MPH versus placebo, certainty in outcomes ranged from low to moderate; for the comparison of omega‐3 versus control, certainty in outcomes was low. Across both comparisons, key issues included study biases, indirect outcome measures and imprecision as a result of small numbers of events as well as confidence intervals which crossed the threshold for an increase and decrease in the likelihood of a given outcome. </p> <p>In particular, it is important to highlight that the comparisons of individual adverse events between active and control arms of both <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> and <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> produced risk ratios with very wide confidence intervals, due to the very small number of individual adverse events occurring (e.g. in <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a>, only two participants experienced nausea and vomiting in the active arm and none did so in the control arm). Our findings relating to the risk of individual adverse events associated with OROS‐MPH and omega‐3 should, therefore, be interpreted with caution. </p> </section> <section id="CD013136-sec-0090"> <h3 class="title" id="CD013136-sec-0090">Potential biases in the review process</h3> <p>We cannot rule out the possibility of publication bias. <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> did not present the exact proportion of participants showing improvement in ADHD symptoms, or exact numbers for the change in total ADHD‐RS score. Data were provided in figures, which prevented accurate estimates and therefore precluded risk ratio and mean difference calculations in this review. We contacted the study authors and asked to obtain these data, however the authors did not respond. We also contacted the authors of <a href="./references#CD013136-bbs2-0001" title="FallahR , EiliaeiS , FerdosianF . Clinical trial of efficacy evaluation of omega-3 with risperidone on seizures frequency in children with refractory epilepsy and attention-deficit/hyperactivity disorder. Iranian Journal of Child Neurology2018;12(4):28-36. [PMID: 30279706]">Fallah 2018</a> to request the relevant outcome data from five participants who were randomised but subsequently discontinued medication after three to four weeks; however, the authors did not respond to our request. We attempted to account for this missing data with best‐and‐worst‐case sensitivity analyses of the proportion of individuals achieving 50% or greater reduction in monthly seizure frequency. </p> </section> <section id="CD013136-sec-0091"> <h3 class="title" id="CD013136-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD013136-bbs2-0096" title="TorresAR , WhitneyJ , Gonzalez-HeydrichJ . Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy &amp; Behavior2008;12(2):217-233. [PMID: 18065271]">Torres 2008</a> conducted a literature review of pharmacological treatment in children with ADHD and epilepsy. Of relevance to this Cochrane Review, the authors summarised findings from <a href="./references#CD013136-bbs2-0002" title="Gonzalez-HeydrichJ , WhitneyJ , WaberD , ForbesP , HsinO , FaraoneSV , et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy &amp; Behavior2010;18(3):229-37. [PMID: 20493783]Gonzalez-HeydrichJ . OROS methylphenidate for attention-deficit/hyperactivity disorder plus epilepsy. P and T (Pharmacy and Therapeutics)2006;31(12):725-6. ">Gonzalez‐Heydrich 2010</a> (which was an ongoing study at the time of the literature review) as well as three additional prospective trials not included in this review due to no evidence of randomisation (<a href="./references#CD013136-bbs2-0006" title="FeldmanH , CrumrineP , HandenBL , AlvinR , TeodoriJ . Methylphenidate in children with seizures and attention-deficit disorder. American Journal of Diseases of Children1989;143(9):1081-6. [PMID: 2672786]">Feldman 1989</a>; <a href="./references#CD013136-bbs2-0009" title="Gross-TsurV , ManorO , van derMeereJ , JosephA , ShalevRS . Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? [Republished from Journal of Pediatrics; 1997 Jan;130(1):40-4; PMID: 9003849]. Journal of Pediatrics1997;130(4):670-4. [PMID: 9432523]">Gross‐Tsur 1997</a>; <a href="./references#CD013136-bbs2-0048" title="GucuyenerK , ErdemogluAK , SenolS , SerdarogluA , SoysalS , KockarAI . Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. Journal of Child Neurology2003;18(2):109-12. [PMID: 12693777]">Gucuyener 2003</a>). Similar to our review, the authors found some evidence for OROS‐MPH improving ADHD symptoms over a short‐term period, but concluded that existing evidence used small sample sizes with relatively infrequent seizures, which may be underpowered to detect an effect of OROS‐MPH on seizure risk. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013136-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013136-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013136-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013136-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: OROS‐MPH versus placebo, Outcome 1: Proportion of people withdrawing from treatment ‐ primary outcome" data-id="CD013136-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: OROS‐MPH versus placebo, Outcome 1: Proportion of people withdrawing from treatment ‐ primary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: OROS‐MPH versus placebo, Outcome 2: Individual adverse drug events ‐ secondary outcome" data-id="CD013136-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: OROS‐MPH versus placebo, Outcome 2: Individual adverse drug events ‐ secondary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 1: Seizure frequency (monthly, postintervention) ‐ primary outcome" data-id="CD013136-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 1: Seizure frequency (monthly, postintervention) ‐ primary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 2: Proportion of individuals withdrawing from treatment ‐ primary outcome" data-id="CD013136-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 2: Proportion of individuals withdrawing from treatment ‐ primary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 3: Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline) ‐ secondary outcome" data-id="CD013136-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 3: Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline) ‐ secondary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 4: Best‐case scenario: proportion of people achieving 50% or more reduction in seizure frequency" data-id="CD013136-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 4: Best‐case scenario: proportion of people achieving 50% or more reduction in seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 5: Worst‐case scenario: proportion of people achieving 50% reduction in seizure frequency" data-id="CD013136-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 5: Worst‐case scenario: proportion of people achieving 50% reduction in seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 6: Proportion of people experiencing adverse drug events ‐ secondary outcome" data-id="CD013136-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 6: Proportion of people experiencing adverse drug events ‐ secondary outcome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013136-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/urn:x-wiley:14651858:media:CD013136:CD013136-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 7: Individual adverse effects" data-id="CD013136-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_t/tCD013136-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only, Outcome 7: Individual adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/media/CDSR/CD013136/image_n/nCD013136-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013136-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Osmotic‐release oral system methylphenidate compared to placebo for people with ADHD and epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Osmotic‐release oral system methylphenidate compared to control for people with ADHD and epilepsy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ADHD and epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> osmotic‐release oral system methylphenidate (OROS‐MPH) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with OROS‐MPH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In logistic regression models calculating the odds of a seizure, significant predictors included the number of days of exposure to placebo or OROS‐MPH (P &lt; 0.005), the drug dose (P &lt; 0.005) and the interaction between them (P = 0.002 when drug dose examined as mg/kg/day and P &lt; 0.001 when examined as absolute dose). Cox proportional hazard models exploring time to seizure and hazard at each dose found that a higher mg/kg/day dose predicted a greater hazard of a seizure (P &lt; 0.001). Days of exposure was not significant, but the interaction between days of exposure and dose was (P &lt; 0.05). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people withdrawing from treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000<br/>(173 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.80<br/>(1.14 to 6.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No participant experienced significant worsening of epilepsy in either the OROS‐MPH or the placebo arm. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing 50% or greater reduction in seizure frequency</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Descriptively, a greater proportion of participants received 'much improved' or 'very much improved' scores for ADHD symptoms on the CGI‐ADHD‐I in the OROS‐MPH arm relative to the placebo arm. Total ADHD‐RS score dropped across both the OROS‐MPH and placebo arms (week of treatment, P &lt; 0.0001), but dropped more rapidly in the OROS‐MPH arm (significant interaction between week of treatment and OROS‐MPH/placebo arm, P &lt; 0.0001). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing adverse drug events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No participants in either the OROS‐MPH or placebo arm experienced serious adverse events. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>ADHD: attention deficit hyperactivity disorder; ADHD‐RS: attention hyperactivity disorder‐rating scale; CGI‐ADHD‐I: Clinical Global Impressions for ADHD—Improvement; CI: confidence interval; OROS‐MPH: osmotic‐release oral system methylphenidate; RCT: randomised controlled trial; RR: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>High certainty: Further research is very unlikely to change our confidence in the estimate of effect.<br/>Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/>Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/>Very low certainty: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: downgraded by one level. This study was rated 'unclear' for random sequence generation and allocation concealment, as well as high for other bias ‐ several authors received funding from McNeil Consumer Health, the provider of active OROS methylphenidate and matching placebo for this study.<br/><sup>b</sup>Indirectness: downgraded by one level. This study did not explore seizure frequency (change from baseline) as an outcome; instead it explored measures of seizure risk (the odds of a seizure on each day of exposure and the number of days of exposure until a seizure occurred).<br/><sup>c</sup>Indirectness: downgraded by one level. This study did not explore seizure severity (change from baseline) as a continuous outcome; instead, seizure severity formed part of the dichotomous outcome 'worsening of epilepsy'. This was defined as (1) a doubling of the highest 14‐day or highest 2‐day seizure rate observed during the 12 months before the trial, (2) a generalised tonic– clonic seizure if none had been experienced in the previous 2 years, or (3) a clinically meaningful intensification in seizure duration or severity.<br/><sup>d</sup>Indirectness: downgraded by one level. This study does not present the exact proportion of participants showing improvement in ADHD symptoms, or exact numbers for the change in total ADHD‐RS score. Data are provided in figures, preventing accurate estimates and therefore precluding risk ratio and mean difference calculations in this review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Osmotic‐release oral system methylphenidate compared to placebo for people with ADHD and epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013136-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ADHD and epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> omega‐3 (with risperidone and previous ASM) </p> <p><b>Comparison:</b> risperidone and previous ASM only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with risperidone &amp; ASM only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omega‐3 (with risperidone &amp; ASM)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure frequency (monthly, postintervention) <br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean seizure frequency was 17 seizures per month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.6 seizures per month lower<br/>(8.96 lower to 4.24 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of individuals withdrawing from treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(12 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/>(0.12 to 3.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizure severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline)<br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/>(93 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.79<br/>(0.84 to 9.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people experiencing adverse drug events<br/>Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/>(65 to 655) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(0.44 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>ADHD: attention deficit hyperactivity disorder; ASM: anti‐seizure medication; CI: Confidence interval; MD: Mean difference; RCT: randomised controlled trial; RR: Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/>High certainty: Further research is very unlikely to change our confidence in the estimate of effect.<br/>Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/>Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/>Very low certainty: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: downgraded by one level. Study rated as high risk of bias for 'blinding of participants and study personnel' and 'incomplete outcome data'.<br/><sup>b</sup>Imprecision: downgraded by one level. Statistical analysis was not paired between baseline and end‐of‐study outcome.<br/><sup>c</sup>Imprecision: downgraded by one level. Only a small number of adverse events occurred, and confidence intervals for the effect on adverse events are consistent with both and appreciable benefit and appreciable harm, so we lowered the certainty.<br/><sup>d</sup>Imprecision: downgraded by one level. Five participants who were randomised were excluded from analyses. Best‐and‐worst‐case sensitivity analyses which made assumptions about 50% or greater reduction in seizure frequency in these participants provided mixed results: confidence intervals of risk ratios suggested both an increase and decrease in the likelihood of 50% or greater reduction.<br/><sup>e</sup>Imprecision: downgraded by one level. Only a small number of adverse events occurred and confidence intervals for the effect on adverse events are consistent with both an appreciable benefit and appreciable harm, so we lowered the certainty. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 (with risperidone and previous ASM) compared to risperidone and previous ASM only for people with ADHD and epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/full#CD013136-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013136-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">OROS‐MPH versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of people withdrawing from treatment ‐ primary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Individual adverse drug events ‐ secondary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Worsened emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">OROS‐MPH versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013136-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Seizure frequency (monthly, postintervention) ‐ primary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of individuals withdrawing from treatment ‐ primary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proportion of people achieving 50% or greater reduction in monthly seizure frequency (change from baseline) ‐ secondary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Best‐case scenario: proportion of people achieving 50% or more reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Worst‐case scenario: proportion of people achieving 50% reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Proportion of people experiencing adverse drug events ‐ secondary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Individual adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Nausea &amp; vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.5 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Omega‐3 (risperidone &amp; previous ASM) versus risperidone and previous ASM only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013136.pub2/references#CD013136-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013136.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013136-note-0036">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013136-note-0026">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013136-note-0032">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013136-note-0023">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD013136-note-0033">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD013136-note-0022">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013136-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013136-note-0029">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD013136-note-0016">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013136-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013136-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013136\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013136\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013136\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013136\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013136\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013136.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013136.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013136.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013136.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013136.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724432864"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013136.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724432868"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013136.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e62b27c8bf3fd',t:'MTc0MDcyNDQzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 